platinum has been researched along with Lung Neoplasms in 618 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (2.75) | 18.7374 |
| 1990's | 35 (5.66) | 18.2507 |
| 2000's | 50 (8.09) | 29.6817 |
| 2010's | 250 (40.45) | 24.3611 |
| 2020's | 266 (43.04) | 2.80 |
| Authors | Studies |
|---|---|
| Avancini, A; Belluomini, L; Casali, M; Dionisi, V; Mazzarotto, R; Menis, J; Milella, M; Palmerio, S; Pilotto, S; Riva, ST; Vincenzi, S | 1 |
| Fang, Z; He, M; Liu, M; Liu, Q; Peng, J; Wei, Y; Wu, B; Yi, F; Zhang, W | 1 |
| Du, X; Duan, W; Li, E; Liu, W; Ren, C; Song, J; Wang, Q; Wang, W; Wang, Y; Wei, S; Xia, S; Zhan, Q; Zhou, Y | 1 |
| Brat, K; Coufalík, P; Hagarová, I; Kuta, J; Venclíček, O; Zvěřina, O | 1 |
| Economidou, SC; Fotopoulos, G; Vrontis, K | 1 |
| Bunn, V; Felip, E; Garcia Campelo, MR; Griffin, C; Jänne, PA; Jin, S; Kim, SW; Kim, TM; Lin, HM; Lin, J; Mehta, M; Mekhail, T; Nguyen, D; Ramalingam, SS; Riely, GJ; Vincent, S; Yang, JC; Zhou, C | 1 |
| Abdel-Rahman, O; Koski, SL | 1 |
| Fujishita, T; Ito, K; Matsubara, T; Okamoto, T; Seto, T; Takamori, S; Toyozawa, R; Yamaguchi, M | 1 |
| Kim, HJ; Kim, JS; Lee, M; Lim, JH; Park, MH; Ryu, JS; Ryu, WK | 1 |
| Chen, J; Cheng, Y; Gao, B; Li, X; Liu, D; Liu, X; Zhang, M; Zhou, H | 1 |
| Chi, X; He, M; Li, H; Shi, X; Sun, Y; Wang, B; Wang, L; Yang, X | 1 |
| Bajor, DL; Biswas, T; Bruno, DS; Cao, S; Dowlati, A; Fu, P; Gerson, SL; Kunos, CA; Machtay, M; Malik, S; Oleinick, NL; Patel, M; Pink, JJ | 1 |
| Amano, Y; Hamaguchi, M; Hamaguchi, S; Hata, K; Hotta, T; Isobe, T; Kurimoto, N; Mitarai, Y; Nagao, T; Nakao, M; Nakashima, K; Okimoto, T; Okuno, T; Tanaka, S; Tanino, A; Tsubata, Y | 1 |
| Li, J; Liu, Q; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X | 1 |
| Fukuda, N; Hara, Y; Horita, N; Kaneko, A; Kaneko, T; Kobayashi, N; Namkoong, H; Somekawa, K; Tagami, Y; Watanabe, K | 1 |
| Blais, N; Bradbury, PA; Dancey, J; Ding, K; Goss, GD; Hiltz, A; Hughes, BGM; Hwang, DM; Joubert, P; Joy, AA; Kulkarni, S; Laurie, SA; Lee, C; Leighl, NB; Mates, M; Rana, P; Stockler, M; Tsao, MS; Underhill, C; Vera-Badillo, F; Yadav, SK | 1 |
| Ando, M; Hakozaki, T; Horinouchi, H; Kataoka, T; Miura, S; Nomura, S; Ohe, Y; Okamoto, I; Sekino, Y; Shiraishi, Y; Tanaka, K | 1 |
| But-Hadzic, J; Ciric, E; Jelercic, S; Stanic, K; Vodusek, AL; Vrankar, M | 1 |
| Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inoue, Y; Inui, N; Karayama, M; Nakamura, Y; Suda, T; Suzuki, Y; Watanabe, H; Yasui, H | 1 |
| Garon, EB; Kim, JS; Peterson, P; Rizzo, MT | 1 |
| Chen, Y; Liu, J; Lv, J; Pan, C; Pan, G; Yang, Y; Zhang, C | 1 |
| Chen, TT; Cunanan, K; Das, M; Gardner, RM; Neal, JW; Padda, SK; Piotrowska, Z; Piper-Vallillo, AJ; Ramchandran, K; Sequist, LV; Wakelee, HA; White, MN | 1 |
| Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inoue, Y; Inui, N; Karayama, M; Nakamura, Y; Suda, T; Suzuki, Y; Yasui, H | 1 |
| Sharma, S; Singh, N; Walia, HK | 2 |
| Ainsworth, B; Ammar, A; Ellis, PA; Pakozdi, T; Ramathal, CY; Riley-Gillis, B; Stolzenburg, LR; Wilsbacher, JL | 1 |
| An, X; Hu, A; Huang, R; Li, H; Li, L; Ni, M; Shi, Y; Xue, C; Yang, W | 1 |
| Bar, J; Daher, S; Dudnik, E; Holtzman, L; Keren, S; Moskovitz, M; Nechushtan, H; Reinhorn, D; Rottenberg, Y; Rovitzky, Y; Shochat, T; Urban, D; Wollner, M | 1 |
| Duan, J; Jiang, Z; Zeng, X | 1 |
| Gao, Y; Liu, X; Long, W; Luan, X; Pan, Y; Song, Y; Wang, Y; Xu, Q; Zeng, F; Zhou, D | 1 |
| Aggarwal, C; Ciunci, C; Cohen, RB; Hwang, WT; Langer, CJ; Mamtani, R; Marmarelis, ME; Singh, A; Yang, YX | 1 |
| Akinboro, O; Beaver, JA; Bi, Y; Bulatao, I; Cheng, J; Chuk, MK; Cohen, R; Donoghue, M; Fiero, MH; Fourie Zirkelbach, J; Fu, W; Gong, Y; He, K; Helms, WS; Herz, J; Jafri, S; Kalavar, S; Larkins, E; Li, H; Liu, J; Mathieu, LN; Mishra-Kalyani, PS; Osborn, BL; Pai-Scherf, LH; Pazdur, R; Ren, Y; Sickafuse, S; Singh, H; Wang, M; Xu, Y; Zhao, H | 1 |
| Almeida, SB; Domingues, TD; Fernandes, G; Honório, M; Santos, CLD; Silva, S; Simões, P; Spencer, AS | 1 |
| Cai, L; Chen, C; Deng, H; Li, S; Lin, X; Liu, M; Qin, Y; Qiu, G; Xie, X; Xie, Z; Yang, Y; Zhou, C | 1 |
| Li, Z; Lu, S | 1 |
| Ge, M; Li, Q; Liang, X; Qi, H; Shi, X; Wang, T; Wang, Y; Zhan, Q; Zhang, L; Zhang, W; Zhong, M | 1 |
| Chang, JH; Chang, TH; Chen, WT; Chien, LN; Chou, YT; Chung, CL; Hong, SY; Hsiao, SH; Lin, SE | 1 |
| Bondarenko, I; Chen, Y; Conev, N; Dalvi, TB; Garassino, MC; Goldman, JW; Havel, L; Hochmair, MJ; Hotta, K; Ji, JH; Jiang, H; Losonczy, G; Mann, H; Musso, E; Özgüroğlu, M; Paz-Ares, L; Poltoratskiy, A; Reinmuth, N; Statsenko, G; Trukhin, D; Voitko, O | 1 |
| Crabb, SJ; Hack, J | 1 |
| Chu, Y; Jiang, M; Liang, H; Sun, H; Yang, F; Yang, T; Zhang, Z | 1 |
| Tian, H; Tian, Y; Yu, J; Zhai, X; Zhu, H | 1 |
| Chen, J; Hong, WX; Liu, JS; Liu, ZQ; Mo, JL; Xiao, Q; Yin, JY | 1 |
| Endoh, H; Fujita, A; Imai, H; Kaburagi, T; Kaira, K; Kanazawa, K; Kasai, T; Kiyoshima, M; Kotake, M; Matsuguma, H; Minato, K; Minemura, H; Nakamura, Y; Sugiyama, T; Suzuki, H; Yamada, Y | 1 |
| Guo, D; Huang, X; Li, H; Liu, T; Miao, S; Shen, M; Wang, M; Wang, Q; Wu, J; Xiao, Z; Zhao, L | 1 |
| Date, H; Inoue, A; Kawaguchi, T; Kenmotsu, H; Kiura, K; Miyaoka, E; Miyawaki, E; Okamoto, I; Sekine, I; Shintani, Y; Shukuya, T; Takahashi, K; Takayama, K; Yamamoto, N; Yoshino, I | 1 |
| Hu, Z; Liao, J; Liu, C; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, Y; Zhao, X | 1 |
| An, T; Chen, H; Chi, Y; Huang, D; Jia, B; Li, J; Lin, G; Wang, J; Wang, Y; Wang, Z; Wu, M; Yang, X; Zhai, X; Zhao, J; Zhuo, M | 1 |
| Huang, Z; Xiong, G | 1 |
| Anderson, AKL; Ansell, P; Aparicio, A; Byers, LA; Byun, J; Cardnell, RJ; Fernandez, L; Fujimoto, J; Gay, CM; Gilbertson, C; He, L; Jendrisak, A; Jones, J; Negrao, MV; Novegil, V; Rocha, P; Schonhoft, JD; Solis Soto, LM; Stewart, CA; Tran, H; Wang, J; Wang, Q; Wang, R; Wang, WL; Wenstrup, R; Wistuba, II; Zhang, B; Zhang, J | 1 |
| Cheong, TF; Chiang, KY; Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
| Asghari, AB; Chai, SM; Creaney, J; Dick, IM; Firth, T; Hansen, J; Lee, YCG; Louw, A; Lynggaard, LA; Meristoudis, C; Panou, V; Røe, OD; Szejniuk, WM; van Vliet, C; Vyberg, M | 1 |
| Li, B; Li, J; Qi, J; Wang, Y; Wei, L; Xu, X; Zhao, S; Zheng, X; Zheng, Y | 1 |
| Abu-Hejleh, T; Allen, BG; Bellizzi, AM; Bodeker, KL; Bossler, AD; Buatti, JM; Buettner, GR; Byrne, MM; Cullen, JJ; Fath, MA; Furqan, M; Hartwig, SM; Henrich, JB; Houtman, JC; Ivanovic, M; Mani, H; Monga, V; Mott, SL; Petronek, M; Pulliam, CF; Smith, BJ; Spitz, DR; Stephens, LM; Varga, SM; Wagner, BA; Zeitler, W; Zhang, J | 1 |
| An, J; Cao, L; Chen, C; Deng, P; Gu, Q; He, B; Hu, C; Jiang, J; Li, M; Qin, L; Yang, H | 1 |
| Bai, KJ; Chang, JH; Chen, HY; Chu, CY; Hsu, YC; Huang, SH; Kuo, LN; Liu, EH; Wang, SY; Yu, MC | 1 |
| Chin, V; Daneshvar, D; Karikios, D; Lim, J; McCloy, R; Murphy, A; Nagrial, A; O'Toole, S; Steinmann, AM; Wong, S | 1 |
| Backenroth, D; Bauml, JM; Bazhenova, L; Bhattacharya, A; Gadgeel, SM; Girard, N; Li, T; Mahadevia, P; Minchom, A; Ou, SI; Trigo, J; Viteri, S | 1 |
| Bozorgmehr, F; Brueckl, WM; Budczies, J; Christopoulos, P; Dintner, S; Eichhorn, F; Faehling, M; Falkenstern-Ge, RF; Frost, N; Griesinger, F; Grohé, C; Hackanson, B; Hong, JL; Janning, M; Kauffmann-Guerrero, D; Kazdal, D; Kirchner, M; Kluck, K; Kollmeier, J; Kuon, J; Kurz, S; Lin, HM; Loges, S; Lüders, H; Misch, D; Reck, M; Roeper, J; Saalfeld, FC; Schulz, C; Shah, R; Stenzinger, A; Sticht, F; Szewczyk, M; Thomas, M; Tufman, A; Wermke, M; Wesseler, C | 1 |
| Gu, X; Lou, G; Shao, L; Shi, Z; Song, Z; Wang, W; Zhang, Y | 1 |
| Lin, A; Luo, P; Shen, W; Yao, Z; Yi, Y; Zhang, J | 1 |
| Ali, WA; Fang, WF; Gan, JD; Huang, YH; Liao, J; Lv, Y; Pang, LL; Zhang, L | 1 |
| Aa, L; Gao, J; Jiang, W; Li, W; Liang, J; Sun, W; Wang, H; Wang, L; Zhou, W | 1 |
| Hara, S; Hata, A; Komatsu, M; Ninomaru, T | 1 |
| Gu, Q; Li, S | 1 |
| Chen, Z; Ke, Y; Lin, Z; Lu, Z; Rao, D; Sun, T; Wu, S; Ye, M; Zhang, D; Zhang, X | 1 |
| Chen, Q; Huang, J; Lin, L; Lv, D; Pan, W; Wu, G; Wu, X; Yan, S | 1 |
| Carlisle, J; Chen, Z; Dhodapkar, M; Leal, T; Liu, Y; Osta, BE; Owonikoko, T; Pakkala, S; Ramalingam, S; Steuer, C | 1 |
| Rodriguez, E; Santos, ES | 1 |
| Fathallah, H; Karim, NA; Morris, JC; Pathrose, P; Perry, A; Starnes, SL; Ullah, A; Wang, J | 1 |
| Cang, S; Chen, G; Fang, J; Han, B; Lin, Y; Mei, X; Stefaniak, V; Sun, L; Wang, S; Wang, Z; Yang, Y; Yang, Z; Yu, Q; Zhang, L; Zhang, W | 1 |
| Arnold, HU; Friesen, TJ; Garrison, SM; Hiatt, JB; Houghton, AM; Liao, SY; MacPherson, D; Martins, R; Norton, JP; Rienhoff, HY; Sandborg, H; Srivastava, S; Sutherland, KD; Wu, F | 1 |
| Chen, X; Dai, L; Fang, J; Han, S; Hu, W; Long, J; Ma, X; Nie, J; Tian, D; Tian, G; Wang, Y; Wu, D; Zhang, J; Zhang, X; Zhang, Z | 1 |
| Bessho, A; Furuya, N; Goto, Y; Harada, T; Kawashima, Y; Misumi, T; Miura, S; Nakahara, Y; Nakamura, Y; Naoki, K; Okamoto, H; Seike, M; Shimokawa, T; Shiraishi, Y; Takiguchi, Y; Tanaka, H; Taniguchi, Y; Tokito, T; Uchiyama, A | 1 |
| Dvorkin, M; Gao, B; Gessner, C; Giorgadze, D; Gogishvili, M; Gullo, G; Kalinka, E; Kaul, M; Laktionov, K; Li, S; Lowy, I; Makharadze, T; McGuire, K; Melkadze, T; Moreno-Jaime, B; Nechaeva, M; Nemsadze, G; Paccaly, A; Passalacqua, R; Penkov, K; Quek, RGW; Rietschel, P; Rozhkova, I; Seebach, F; Weinreich, DM; Yancopoulos, GD | 1 |
| Deng, W; Deng, Y; Duan, Z; Liao, R; Luo, J | 1 |
| Cao, L; Fan, Y; Fang, J; He, J; Hu, J; Liu, W; Liu, Y; Lu, S; Shi, J; Wang, Z; Xia, J; Yi, J; Zhou, J | 1 |
| Chen, LH; Du, Y; Ouyang, HF; Ti, XY; Wu, S; Xu, X; Zhang, Y | 1 |
| Imai, H; Kaburagi, T; Kagamu, H; Kaira, K; Kanazawa, K; Kishikawa, T; Masubuchi, K; Minato, K; Minemura, H; Nagai, Y; Shiihara, J; Shiono, A; Takechi, H; Taniguchi, H; Tsuda, T; Umeda, Y; Wasamoto, S; Yamada, Y | 1 |
| Chen, L; Chen, Y; Deng, P; Dong, Y; Han, B; Kong, T; Liu, D; Qian, F; Yang, H; Zhang, B; Zhang, W; Zhang, Y | 1 |
| Minegishi, K; Nagatsu, K; Obata, H; Ogawa, M; Sudo, H; Sugyo, A; Tsuji, AB; Zhang, MR | 1 |
| Guo, Z; Jia, Y; Song, R; Wu, C; Zhang, R; Zhang, S; Zhang, X; Zhao, Y | 1 |
| Dunne, B; Harden, S; Hoang, W; John, T; Leal, JL; Xue, J | 1 |
| Cui, S; Li, L; Lu, X; Xiao, M; Xue, P; Yu, T; Zhang, G; Zhang, H; Zhang, L | 1 |
| Liu, X; Shi, Y; Xu, J; Yang, S | 1 |
| Chang, GC; Chen, KC; Hsu, KH; Huang, JW; Huang, YH; Tseng, JS; Wu, JJ; Yang, TY | 1 |
| Luo, T; Ma, H; Ren, X; Yu, S; Zhou, M | 1 |
| Chen, C; Chen, H; Chen, T; Du, W; Fu, S; He, LN; Hong, S; Lin, Z; Zhang, X; Zhou, Y | 1 |
| Choi, CM; Choi, J; Jang, TW; Kim, EY; Lee, JE; Lee, KY; Lee, SH; Lee, SY; Oh, IJ; Park, DW; Park, SH | 1 |
| Kang, HS; Kim, JW; Kim, SJ; Kim, SK; Lee, SH; Lim, JU; Shin, AY; Yeo, CD | 1 |
| Abbie, E; Boyne, DJ; Brenner, DR; Cheung, WY; Eaton, K; Elia-Pacitti, J; Ewara, EM; Gogna, P; Hu, LXY; Jarada, TN; O'Sullivan, DE; Pabani, A; Rose, JB; Yusuf, A | 1 |
| Bondarenko, I; Brady, KJS; Chen, CI; Cicin, I; Gogishvili, M; Gullo, G; Gümüş, M; Harnett, J; Ivanescu, C; Kilickap, S; Konidaris, G; Li, S; Mastey, V; Naumann, U; Özgüroğlu, M; Reaney, M; Rietschel, P; Sasane, M; Sezer, A; Turk, HM | 1 |
| Gao, Y; Li, B; Liu, Y; Wang, Y; Zhang, T; Zhang, Z; Zhao, C | 1 |
| Bruns, CJ; Hekmat, K | 1 |
| Hou, H; Jiang, M; Li, T; Sun, D; Wang, Y; Zhang, C; Zhang, X; Zhou, N; Zhu, J | 1 |
| Hua, X; Liu, H; Lv, T; Song, Y; Wu, X; Xu, K; Zhan, P; Zhang, F | 1 |
| Baglivo, S; Bellezza, G; Bonaiti, A; Colafigli, C; Di Girolamo, B; Ludovini, V; Mandarano, M; Matocci, R; Metelli, N; Metro, G; Roila, F | 1 |
| Al-Hashami, Z; Ho, C; Leung, B; Rittberg, R | 1 |
| Chen, C; Chen, N; Chen, R; Chen, X; Cong, X; Cui, G; Cui, J; Jia, L; Li, W; Liu, Z; Lu, J; Ma, K; Niu, C; Song, W; Wang, N; Wang, X; Xu, Y; Yang, L; Zhao, Y | 1 |
| Jiang, A; Lin, A; Luo, P; Mou, W; Zhang, J; Zhu, L | 1 |
| Aggarwal, H; Muehlenbein, CE; Ndirangu, K; Thom, H; Tongbram, V; Winfree, KB; Zhu, E | 1 |
| Arunachalam, A; Catherine Pietanza, M; Frederickson, AM; Zhang, I; Zhao, B | 1 |
| Brouwer, J; de Jong, C; Deneer, VHM; Egberts, TCG; Herder, GJM; Ten Heuvel, A; van der Meer, FS; van Haarlem, SWA; van Lindert, ASR | 1 |
| Bennouna, J; Bodot, L; Boudoussier, A; Chatellier, T; Curcio, H; Demontrond, P; Dumenil, C; Gourraud, PA; Guardiolle, V; Hiret, S; Hulo, P; Mayenga, M; Mazieres, J; Pons-Tostivint, E; Porte, M; Rabeau, A; Veillon, R | 1 |
| Abo Elkasem, F; Bahnassy, A; Gaafer, R; Khorshid, O; Wahba, NI | 1 |
| Azuma, K; Fujimoto, D; Hasegawa, K; Hayakawa, D; Hayashi, H; Iwama, E; Kato, T; Nakagawa, K; Nakamura, A; Nosaki, K; Oki, M; Shimokawa, M; Tachihara, M; Takahashi, T; Takeda, M; Tanaka, H; Watanabe, Y; Yamaguchi, K; Yamamoto, N; Yamamoto, S | 1 |
| Akerley, W; Haaland, B; Kerrigan, K; Patel, S; Puri, S; Sama, S; Sinnott, JA | 1 |
| Frances, N; Geiger, K; Hartung, N; Henrich, A; Holdenrieder, S; Huisinga, W; Joerger, M; Kloft, C; Nassar, YM; Ojara, FW | 1 |
| Adamo, V; Cantale, O; Castorina, L; Chillari, F; Colarossi, C; Esposito, F; Franchina, T; Giuffrida, D; Puliafito, I; Ricciardi, GRR; Russo, A; Sciacca, D; Vitale, MP | 1 |
| Eom, JS; Jo, EJ; Kim, KU; Kim, MH; Kim, SH; Lee, K; Lee, MK; Mok, J; Park, HK | 1 |
| Bigay-Game, L; Bylicki, O; Castera, M; Chouaid, C; Clarisse, B; Daniel, C; Decroisette, C; Doubre, H; Geier, M; Greillier, L; Grellard, JM; Guisier, F; Martins-Lavinas, PH; Monnet, I; Moreau, D; Peloni, JM; Radj, G; Ricordel, C; Subtil, F; Swalduz, A; Toffart, AC; Tomasini, P | 1 |
| Aldea, M; Boudier, B | 1 |
| Batista de Carvalho, ALM; Batista de Carvalho, LAE; Laginha, RC; Marques, J; Marques, MPM; Martins, CB; Santos, IP; Silva, JD | 1 |
| Balbach, ML; Bestvina, C; Camidge, DR; Hsu, R; Iams, WT; Kim, C; Leal, T; Marmarelis, ME; Mehta, K; Nieva, J; Patil, T; Phillips, S; Robinson, MA; Sacher, A; Sackstein, PE; Sethakorn, N; Velcheti, V; Wang, X | 1 |
| Carbone, DP; Furuya, N; He, K | 1 |
| Arai, D; Ito, K; Kaira, K; Kajiwara, T; Kobayashi, K; Kodama, H; Miura, K; Miyanaga, A; Mizutani, H; Mori, K; Nakamura, A; Ninomiya, T; Oba, T; Tamiya, M; Yamaguchi, O; Yanagitani, N | 1 |
| Bu, X; Cao, ZR; Duan, YF; Huang, W; Li, L; Liu, RY; Liu, TY; Luo, C; Yang, MJ; Yuan, XX; Yue, X | 1 |
| Jo, DY; Ko, YB; Lee, HJ; Lee, MW; Ryu, H; Song, IC; Yeon, SH; Yun, HJ | 1 |
| Beaver, JA; Ghosh, S; Goldberg, KB; Jafri, S; Kalavar, S; Larkins, E; Mathieu, LN; Mishra-Kalyani, PS; Pazdur, R; Singh, H; Sinha, AK | 1 |
| Kimura, T; Kurita, T; Miyoshi, AI; Ueda, Y; Yoshino, K | 1 |
| Chen, M; Han, H; Lin, X; Lv, T; Qiu, G; Song, Y; Xie, J; Xu, K; Ye, J; Zhan, P | 1 |
| Chen, X; Cui, JW; Ding, X; Han, FJ; He, H; Li, FQ; Li, WQ; Li, ZZ; Niu, C; Qian, L; Tian, HM; Wang, HY; Xu, JT | 1 |
| Deng, W; Dong, X; Jiang, L; Li, L; Liao, A; Min, Y; Shi, A; Yang, D; Yu, H; Yu, R; Zhao, J | 1 |
| Jin, C; Li, R; Xiong, H; Zhao, W | 1 |
| Atagi, S; Endo, T; Fujita, Y; Kanazu, M; Kita, T; Mizuki, F; Mori, M; Motegi, M; Okano, Y; Saito, R; Shimokawa, M; Sukoh, N; Takata, S; Takenoyama, M; Tamura, A | 1 |
| Hong, JL; Jin, S; Lin, HM; Lin, J; Mehta, M; Neal, JW; Nguyen, D; Ou, SI; Yin, Y; Zhang, P | 1 |
| Adeyemi, A; Boccuti, A; Caisip, C; Hanvesakul, R; Jansen, JP; Naveh, N; Park, JE; Rengarajan, B; Wilson, FR | 1 |
| Alamgeer, M; Cain, JE; Chen, J; DeVeer, M; Ganju, V; Garama, DJ; Gough, DJ; Guanizo, AC; Inampudi, C; Jakasekara, WSN; Luong, Q; Thakur, N; Watkins, DN | 1 |
| Ni, J; Si, X; Wang, H; Zhang, L; Zhang, X | 1 |
| Akinboro, O; Amatya, A; Beaver, JA; Bi, Y; Drezner, N; Fourie-Zirkelbach, J; Korsah, K; Larkins, E; Mixter, B; Pazdur, R; Runyan, J; Singh, H; Tang, S; Zhao, M | 1 |
| Chihara, Y; Date, K; Harada, T; Ishida, M; Iwasaku, M; Kanda, H; Kim, YH; Morimoto, K; Shiotsu, S; Takayama, K; Takeda, T; Takemura, Y; Tamiya, N; Tokuda, S; Yamada, T; Yoshimura, A | 1 |
| Baranwal, M; Sharma, S; Singh, N; Singh, S | 1 |
| Artaç, M; Bozcuk, H; Eser, İ; Mutlu, H | 1 |
| Dvorkin, M; Gessner, C; Giorgadze, D; Gogishvili, M; Gullo, G; Ivanescu, C; Kalinka, E; Konidaris, G; Laktionov, K; Makharadze, T; Melkadze, T; Moreno-Jaime, B; Nechaeva, M; Nemsadze, G; Passalacqua, R; Penkov, K; Quek, RGW; Rietschel, P; Rozhkova, I | 1 |
| Bleckmann, A; Frost, N; Griesinger, F; Grohé, C; Janning, M; Kollmeier, J; Reck, M; Reinmuth, N; Sebastian, M; Thomas, M | 1 |
| Beebe, KD; Conroy, JM; Davison, JM; Eisner, JR; Farhangfar, C; Farhangfar, F; Guo, Y; Hayes, DN; Mayhew, GM; Milburn, MV; Mileham, KF; Shibata, Y; Uronis, JM | 1 |
| Chen, J; Deng, C; Deng, X; Huang, X; Li, H; Miao, S; Mu, L; Wang, Q; Wu, J; Xiao, Z; Yang, S | 1 |
| Abbar, B; Bergeret, S; Campedel, L; Foka Tichoue, H; Gougis, P; Hassani, L; Jaffrelot, L; Lassoued, D; Morardet, L; Perrier, A; Roussel-Simonin, C; Spano, JP; Taillade, L; Veyri, M; Vozy, A; Wassermann, J | 1 |
| Chao, HS; Chen, YM; Chiang, CL; Hsiao, TH; Huang, HC; Liao, YT; Luo, YH; Shen, CI; Sun, RL; Tseng, YH; Wang, LC; Yeh, YC | 1 |
| Atsumi, K; Hirose, T; Hisakane, K; Nishijima, N; Okano, T; Seike, M; Takahashi, S; Taniuchi, N; Tozuka, T | 1 |
| Gu, X; Guan, Y; Hao, Y; Song, Z; Sun, Y; Wang, W; Xiang, J; Yao, Q; Zeng, X | 1 |
| Agarwal, M; Almquist, D; Ernani, V; Langlais, BT; Leventakos, K; Liu, A; Manochakian, R; Yu, NY | 1 |
| Fan, Y; Fang, J; Kang, M; Li, W; Li, X; Liu, Q; Ma, Z; Wang, J; Wang, N; Xie, Q; Xiong, A; Xu, M; Xu, T; Zhi, L; Zhou, C; Zhuang, W | 1 |
| Arriola, E; Cruz-Castellanos, P; Dómine, M; García-Campelo, R; Insa, A; Juan Vidal, O; Morán, T; Reguart, N; Sullivan, I; Zugazagoitia, J | 1 |
| Biggane, AM; Califano, R; Cappuzzo, F; Connors, M; Cortinovis, D; Han, B; Höglander, E; Hu, Y; Huang, D; Kowalski, D; Le, AT; Lee, SM; Liu, G; Mak, MP; Morris, S; Palmero, R; Peters, S; Prabhash, K; Reck, M; Reyes Contreras, J; Rittmeyer, A; Schulz, C; Szczesna, A; Talbot, T; Vicente, D; Vollan, HK | 1 |
| O'Sullivan, H; Popat, S | 1 |
| Fujita, A; Fushimi, K; Iwai, C; Jo, T; Konishi, T; Matsui, H; Michihata, N; Yasunaga, H | 1 |
| Hayashi, H; Kasahara-Kiritani, M; Nishio, M; Takahashi, M; Tsuchiya, H | 1 |
| Goto, Y; Gyotoku, H; Harada, D; Kogure, Y; Murakami, S; Ninomiya, K; Nomura, S; Okamoto, H; Okishio, K; Okuma, Y | 1 |
| Huang, Z; Li, D; Lin, L; Liu, Z; Zhang, G; Zhong, J; Zhuang, W | 1 |
| Alessi, JV; Arbour, KC; Arcila, ME; Awad, MM; Baine, MK; Egger, JV; Elkrief, A; Fei, T; Hellmann, MD; Kalvin, HL; Kris, MG; Ladanyi, M; Lamberti, G; Lito, P; Plodkowski, A; Riccuiti, B; Riely, GJ; Rizvi, H; Rudin, CM; Schoenfeld, AJ; Thummalapalli, R | 1 |
| Chang, Y; Chen, C; Hu, F; Huang, C; Huang, H; Jin, H; Jin, R; Jin, Z; Ma, Y; Wu, S; Xie, Q; Xue, Z; Zhao, L; Zheng, M | 1 |
| Akamatsu, H; Hida, T; Inui, N; Kang, JH; Kim, HR; Lee, JS; Lee, KH; Nakagawa, K; Nishio, M; Ohe, Y; Sugawara, S; Takahashi, S; Tamura, T; Tanaka, H; Yamamoto, N; Yang, CT; Yoshida, T; Yu, CJ | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
| Besse, B; Bironzo, P; Chih-Hsin Yang, J; Dong, Q; Fan, PD; Felip, E; Goto, Y; Hayashi, H; Jänne, PA; John, T; Johnson, ML; Kao, S; Kim, DW; Kozuki, T; Lee, SH; Massarelli, E; Patel, J; Patel, P; Paz-Ares, L; Reck, M; Reckamp, KL; Sellami, D; Shrestha, P; Smit, E; Sporchia, A; Sternberg, DW; Wu, YL; Yoh, K; Yu, HA | 1 |
| Choi, CM; Ji, W; Kim, J; Lee, JC | 1 |
| Aiba, T; Domeki, Y; Kawana, S; Kawashima, Y; Kimura, Y; Nakamura, A; Sugawara, S; Sugisaka, J; Toi, Y; Yamanda, S | 1 |
| Berta, J; Bogos, K; Döme, B; Ferencz, B; Fillinger, J; Horváth, L; Lantos, A; Megyesfalvi, Z; Rényi-Vámos, F | 1 |
| Patel, JD; Patel, S | 1 |
| Baak, JPA; Feng, J; Guo, H; Huang, X; Li, H; Zhu, L | 1 |
| Jiang, Y; Li, J; Tang, W; Xi, J; Zhao, M; Zheng, X | 1 |
| Botticelli, A; Brambilla, M; Cappuzzo, F; Cecere, FL; Ciliberto, G; Cortesi, E; Di Civita, MA; Facciolo, F; Forde, PM; Gallina, FT; Gelibter, AJ; Giusti, R; Landi, L; Liu, SV; Marinelli, D; Melis, E; Nisticò, P; Novello, S; Occhipinti, M; Pannunzio, S; Porciello, N; Roberto, M; Santini, D; Tajè, R; Torchia, A; Verrico, M | 1 |
| Hara, Y; Hashimoto, H; Horita, N; Kaneko, A; Kaneko, T; Kobayashi, N; Kubo, S; Kudo, M; Matsumoto, H; Somekawa, K; Teranishi, S; Watanabe, K | 1 |
| Chisaki, Y; Minamide, J; Nakano, H; Yano, Y | 1 |
| Gu, W; He, M; Li, Z; Zhuang, M; Zhuang, W | 1 |
| Gerner-Rasmussen, J; Hansen, O; Holm, B; Jeppesen, N; Langer, SW; Mau-Sørensen, M; McCulloch, T; Nielsen, HA; Nyhus, CH; Rytter, C; Wedervang, K | 1 |
| Cho, BC; Girard, N; Kim, TM; Kleinman, NJ; Lim, CTK; Low, GKM; Murota, M; Yang, Y; Yu, DY; Zhuo, J | 1 |
| García-Pardo, M; Mezquita, L | 1 |
| Ben, XS; Dong, S; Jiang, BY; Li, HR; Liao, RQ; Lin, JT; Liu, K; Liu, SM; Liu, SY; Nie, Q; Qiao, GB; Tu, HY; Wang, BC; Wang, Q; Wu, W; Wu, YL; Yan, HH; Yan, LX; Yang, JJ; Yang, XN; Zhong, WZ; Zhou, Q | 1 |
| Dai, G; Gao, M; Hu, J; Li, L; Ma, J; Wang, Y; Yan, H; Yang, X; Zhang, X; Zhao, Y | 1 |
| Arulananda, S; John, T; Mitchell, P | 1 |
| Edwards, A; Falk, S; Hackshaw, A; Hatton, M; Jones, R; Lal, R; Lee, SM; Lewanski, C; Ngai, Y; Rudd, R; Skailes, G; Toy, E; Upadhyay, S; Woll, PJ | 1 |
| Chang, MC; Chiu, CH; Chou, PH; Lin, HH; Liu, CL; Ma, HL; Wang, JP; Wang, ST | 1 |
| Hamburger, T; Kadouri, L; Lipson, D; Nechushtan, H; Peretz, T; Rottenberg, Y; Zick, A | 1 |
| Chen, C; Chen, T; Fu, S; He, LN; Hong, S; Li, H; Lin, Z; Wang, Y; Zhang, L; Zhang, X; Zhou, Y | 1 |
| Ma, F; Peng, L; Peng, Y; Tan, C; Wan, X; Yi, L; Zeng, X | 1 |
| Goetze, TO | 1 |
| Han, X; Han, Y; He, X; Huang, Y; Pi, J; Shi, Y; Song, Y; Tan, Q; Wu, D; Yang, J; Yang, S; Yao, J; Zhang, Z; Zhou, S; Zuo, L | 1 |
| Adjei, AA; Aubry, MC; Bertino, E; Dakhil, SR; Dy, GK; Lee Hann, C; Mandrekar, SJ; Molina, JR; Nieva, JJ; Sachs, BA; Schenk, EL; Schild, SE; Tan, AD; Wadsworth, TW | 1 |
| Chin, E; Dagogo-Jack, I; Digumarthy, SR; Gainor, JF; Lin, JJ; Ou, SI; Plodkowski, AJ; Riely, GJ; Rooney, M; Schoenfeld, AJ; Shaw, AT; Yeap, BY; Zhu, VW | 1 |
| Escriu, C; Sallam, M; Wong, H | 1 |
| Ilonen, I; Järvinen, T; Koli, K; Lauri, H; Lemström, K; Myllärniemi, M; Ollila, H; Paajanen, J; Räsänen, J; Ritvos, O; Rouvinen, E; Sutinen, E | 1 |
| Li, K; Lin, A; Luo, P; Wei, T; Zhang, J | 1 |
| Lee, SH; Park, K; Park, S | 1 |
| He, Z; Li, Y; Liu, Y; Niu, Y; Shi, H; Xu, M; Xu, Q; Zhang, Y; Zhu, J | 1 |
| Ikeda, N; Kajiwara, N; Kudo, Y; Maehara, S; Matsubayashi, J; Minna, JD; Ohira, T; Otaki, Y; Shimada, Y | 1 |
| Chung, LY; Huang, HJ; Sun, GH; Sun, KH; Tang, SJ; Wu, YC; Yang, KC | 1 |
| Arriola, E; Bellosillo, B; Carcereny, E; Chaib, I; Clavé, S; Dalmases, A; Gibert, J; Hardy-Werbin, M; Longarón, R; Morán, T; Piquer, G; Rocha, P; Salido, M; Taus, Á | 1 |
| Feng, FC; Gu, C; Han, D; He, HL; Peng, WP; Wang, ZC; Xu, Y; Zhou, XM | 1 |
| Ishiki, H; Kiuchi, D; Kubo, E; Satomi, E; Shimizu, M; Tanaka, T; Yokota, S | 1 |
| Chen, CY; Chen, KY; Shih, JY; Yu, CJ | 1 |
| Bradford, DS; Crane, J; Deal, AM; Irvin, W; Lee, C; Morgensztern, D; Muss, HB; Pecot, C; Pennell, N; Socinski, M; Stevenson, JP; Stinchcombe, T; Villaruz, LC; Weiss, JM; West, HJ | 1 |
| Alexandris, E; Brustugun, OT; Cuyun Carter, G; Gans, S; Garon, EB; Gautschi, O; Iglesias Docampo, L; Kalofonos, H; Kim, JH; Lee, P; Orlov, SV; Oton, AB; Pérol, M; Reck, M; Scagliotti, GV; Socinski, MA; Stefaniak, VJ; Thomas, M; Wolff, K; Zimmermann, AH | 1 |
| Bian, Q; Kong, FK; Leung, KC; Ng, M; Tang, FK; Tse, AK; Tse, YC; Yam, VW; Zhu, J | 1 |
| Chang, GC; Chen, YM; Chih-Hsin Yang, J; Chiu, CH; Chong, IW; Ho, CC; Hsia, TC; Hung, JY; Lin, MC; Su, WC; Wang, CC; Wu, SY; Yang, TY; Yu, CJ | 1 |
| Bas, T; Bischoff, HG; Boyer, M; Cheng, SY; Clingan, P; Dómine, M; Esteban, E; Felip, E; Gadgeel, S; Garassino, MC; Garon, EB; Gray, JE; Grossi, F; Hochmair, MJ; Hui, R; Jennens, RR; Kurata, T; Novello, S; Peled, N; Pietanza, MC; Powell, SF; Reck, M; Rodríguez-Abreu, D; Rubio-Viqueira, B; Speranza, G; Yang, J | 1 |
| Arnold, SM; Baggstrom, MQ; Chansky, K; Crowley, JJ; Hamm, J; Leggas, M; Rosales, J; Sanborn, RE; Thompson, MA; Villano, JL; Waqar, SN; Willis, M | 1 |
| Arriola, E; Cui, ZL; Garon, EB; Levy, B; Mekhail, T; Molife, C; Pérol, M; Winfree, KB | 1 |
| Bai, W; Bepler, G; Caruso, JA; Chen, W; Heyza, J; Hu, C; Hu, CL; Jang, H; Lou, Z; Malysa, A; Moses, N; Patrick, S; Polin, L; Stemmer, P; Wang, C; Xiang, S; Zhang, M; Zhang, XM | 1 |
| Liu, L; Liu, Y; Mi, X; Shao, M; Wang, J | 1 |
| Awad, MM; Cheema, PK; Csőszi, T; Ebiana, V; Gottfried, M; Gümüş, M; Kalemkerian, GP; Kato, T; Kim, HR; Luft, A; Luo, Y; Mazieres, J; Navarro, A; Orlandi, FJ; Peters, S; Pietanza, MC; Rodriguez-Abreu, D; Rudin, CM; Wollner, M; Yang, JC | 1 |
| Si, X; Wang, H; Wang, M; You, Y; Zhang, L; Zhang, X | 1 |
| Chu, TQ; Han, BH; Lou, YQ; Xu, JL; Zhong, H; Zhong, RB | 1 |
| Chen, G; Chen, J; Fan, Y; Fang, J; Gao, G; He, J; Hu, Y; Li, X; Lin, X; Shu, Y; Wang, Q; Wu, F; Zhang, Y; Zhao, J; Zhou, C; Zhu, X; Zou, J | 1 |
| Gao, RK; Hou, W; Li, HZ; Li, J; Zhang, Y; Zhu, GH | 1 |
| Kanazawa, S; Kiura, K; Shien, K; Soh, J; Takahashi, Y; Toyooka, S; Yamamoto, H; Yamane, M; Yanai, H | 1 |
| Jiang, Y; Wang, X | 1 |
| Cheng, Y; Cui, J; Leaw, SJ; Liu, Z; Ma, X; Ma, Y; Ma, Z; Shu, Y; Tan, W; Wang, J; Wang, Z; Wu, Y; Zhang, Y; Zhao, J | 1 |
| Bi, M; Cang, S; Chen, G; Cheng, Y; Fang, J; Feng, J; Han, B; He, Z; Li, B; Li, J; Li, W; Lu, Y; Ma, R; Mei, X; Ren, X; Song, Y; Wang, L; Wang, S; Wang, Y; Wang, Z; Xie, C; Yang, N; Yang, Y; Yang, Z; Yu, Q; Yu, Z; Zhang, L; Zhang, W; Zhang, Y; Zhao, Y; Zhou, H; Zhou, J; Zhou, R; Zhu, D | 1 |
| He, L; Huang, X; Li, Y; Lou, Y; Wang, L; Yang, H; Zhang, Y | 1 |
| Funasaka, C; Kageyama, A; Kanemasa, Y; Omuro, Y; Shimoyama, T | 1 |
| Bierbach, U; Caruso, SR; Day, CS; Rose, PK; Watkins, NH; Yao, X; Zhang, S | 1 |
| Seetharamu, N; Singh, N | 1 |
| Ahn, MJ; Akamatsu, H; Delmonte, A; Han, JY; He, Y; John, T; Kim, SW; Laskin, J; Laus, G; Mann, H; Miranda, M; Mok, TS; Papadimitrakopoulou, VA; Ramalingam, SS; Rukazenkov, Y; Sebastian, M; Shepherd, FA; Su, WC; Theelen, WSME; Wu, YL | 1 |
| Ahmed, MU; Al-Mamun, MMA; Apu, MNH; Bushra, MU; Hasnat, A; Islam, MR; Islam, MS; Nahid, NA; Rivu, SF; Sifat, AE | 1 |
| Auclin, E; Besse, B; Boselli, L; Caramella, C; Cassard, L; Chaput, N; Desnoyer, A; Duchemann, B; Farhane, S; Ferrara, R; Garassino, MC; Grivel, J; Hendriks, L; Jouniaux, JM; Marabelle, A; Mezquita, L; Naigeon, M; Planchard, D; Proto, C; Remon, J; Sangaletti, S; Soria, JC; Texier, M; Voisin, AL | 1 |
| Li, M; Liao, C; Wang, L; Wei, Y; Yi, F; Yu, J; Zhang, S; Zhang, W | 1 |
| Gao, S; Gou, J; He, H; Tang, X; Wang, Y; Wu, R; Xue, Y; Yin, T; Zhang, Y | 1 |
| Chen, Y; Dvorkin, M; Garassino, MC; Goldman, JW; Havel, L; Hochmair, MJ; Hotta, K; Ji, JH; Jiang, H; Laud, PJ; Losonczy, G; Özgüroğlu, M; Patel, N; Paz-Ares, L; Poltoratskiy, A; Reinmuth, N; Shire, N; Statsenko, G; Trukhin, D; Voitko, O | 1 |
| Bierbach, U; Ding, S; Hackett, CL; Hackett, RG; Liu, F | 1 |
| Forde, PM; Lam, VK | 1 |
| Antonia, SJ; Boyle, TA; Chiappori, A; Conejo-Garcia, JR; Creelan, B; Dilling, TJ; Grass, GD; Gray, J; Haura, E; Karimi, AM; Kim, S; Lannon, A; Latifi, K; Li, J; MacMillan, G; Perez, BA; Powell, C; Rose, T; Rosenberg, S; Saller, J; Saltos, A; Schell, MJ; Shafique, M; Tanvetyanon, T; Wang, M | 1 |
| Sun, AL; Zhi, LJ | 1 |
| de Jong, C; Deneer, VHM; Herder, GJM | 1 |
| De Petris, L; Kanter, L; Lewensohn, R; Ortiz-Villalón, C; Tendler, S; Viktorsson, K | 1 |
| Hu, F; Liu, Y; Zhao, L | 1 |
| Chu, Q; Damaraju, VL; Mazurak, V; Murphy, RA; Robinson, L; Sawyer, MB; Stanislaus, AE; Teleni, L; van der Meij, BS | 1 |
| Gupte-Singh, K; Le, TK; Lubinga, SJ; Penrod, JR; Smith, CB; Stenehjem, DD; Zhang, Y | 1 |
| Eguren-Santamaria, I; Salas-Benito, D; Sanmamed, MF | 1 |
| Asahina, H; Isobe, T; Kagamu, H; Kikuchi, T; Kobayashi, K; Maemondo, M; Morita, S; Oizumi, S; Okamoto, I; Seike, M; Sugio, K; Takahashi, K; Tanaka, K | 1 |
| Cui, L; Jiao, X; Zhang, Z; Zhao, N | 1 |
| Yang, Y; Zhang, L; Zhou, H | 1 |
| Gibert, Y; Irihamye, EN; Monroe, JD; Moolani, SA; Smith, ME; Speed, JS | 1 |
| Alvisi, MF; Bettini, AC; Broggini, M; Caiola, E; Cecere, FL; De Maglie, M; Fabbri, A; Ganzinelli, M; Garassino, MC; Linardou, H; Lo Russo, G; Marabese, M; Milella, M; Murray, S; Psyrri, A; Romanelli, P; Rulli, E | 1 |
| Ackermann, C; Califano, R; Ortega-Franco, A; Paz-Ares, L | 1 |
| Gurunathan, S; Jeyaraj, M; Kang, MH; Kim, JH | 1 |
| Ballinger, M; Flynn, S; Hegde, PS; Kowanetz, M; Mocci, S; Patil, NS; Sandler, A; Zou, W | 1 |
| Chen, B; Lin, J; Peng, J; Xue, L | 1 |
| Bar, J; Daher, S; Dudnik, E; Lobachov, A; Mandelboim, R; Moskovitz, M; Nechushtan, H; Rotem, O; Rottenberg, Y; Shochat, T; Urban, D; Wollner, M; Zer, A | 1 |
| Dotsu, Y; Fukuda, M; Fukuoka, J; Gyotoku, H; Honda, N; Miyazaki, T; Mukae, H; Nakao, T; Obase, Y; Ozasa, M; Sakamoto, N; Suyama, T; Takemoto, S; Taniguchi, H; Tomohito, K; Umeyama, Y; Yamaguchi, H | 1 |
| Bernabé, R; Bosch-Barrera, J; Camerini, A; Ceresoli, GL; Ciuleanu, TE; de Marinis, F; Gautier, S; Grossi, F; Kowalski, D; Laundreau, P; Montanino, A; Morabito, A; Pasello, G; Ramlau, R; Ta Thanh Minh, C | 1 |
| Bajars, M; Barlesi, F; Manitz, J; Özgüroğlu, M; Park, K; Ruisi, M; Spigel, D; Vansteenkiste, J; Yang, JC | 1 |
| Goldman, JW; Paz-Ares, L | 1 |
| Horita, N; Katakura, S; Takeshi, K | 1 |
| Beaver, JA; Goldberg, KB; Kluetz, PG; Larkins, E; Li, X; Mathieu, L; Mishra-Kalyani, P; Pai-Scherf, L; Pazdur, R; Rodriguez, L; Shah, S; Singh, H; Theoret, MR; Vallejo, J | 1 |
| Gao, C; Hu, L; Li, C; Lv, D; Mao, X; Wang, T; Xu, Y | 1 |
| Bandyopadhyay, A; Behera, D; Sharma, S; Singh, N | 1 |
| Aerts, J; Gadgeel, SM; Garon, EB; Kim, JS; Muehlenbein, CE; Peterson, P; Rizzo, MT | 1 |
| Huang, J; Li, L; Liu, H; Lv, Y; Wang, F; Yin, F; Zhao, C; Zheng, Q | 1 |
| Abakumov, MA; Abdul Razak, IB; Aisa, HA; Akhmirov, RT; Aladinskaya, AV; Allem, JP; Allu, SR; Ambale-Venkatesh, B; Anasori, B; Arizcorreta, A; Armentrout, PB; Baumann, H; Beloglazkina, EK; Ben-Elyiahu, Y; Ber, AP; Berthon, C; Bettelheim, A; Bluemke, DA; Bonsignore, M; Bordet, A; Borruso, A; Boxer, MB; Bress, AP; Brimacombe, KR; Brown, DE; Brüggemann, M; Cafeo, A; Cao, K; Cao, L; Carnicelli, J; Carr, JC; Cavallo, L; Cazin, CSJ; Cheff, DM; Chen, G; Chen, H; Chen, J; Chen, R; Chen-Sankey, JC; Cheng, C; Cheng, Y; Cheruku, RR; Chida, N; Choi, K; Chu, M; Cipolli, M; Colantonio, LD; Collado, A; Cook, J; Cordes, DB; Covey, J; Cuesta-Sancho, S; Davis, MI; Demireva, M; Derington, CG; Di Rosa, G; Dicanio, D; Dong, G; Dontsova, OA; Dormanesh, A; Dovrat, G; Duan, XM; Duarte, DA; Efthymiou, S; Erofeev, AS; Falivene, L; Fang, Y; Feng, D; Fernandes, VRS; Finko, AV; Freitag, TM; Frye, S; Gachot, C; Gao, S; Garanina, AS; Getya, D; Girón-González, JA; Girón-Ortega, JA; Gitsov, I; Gorelkin, PV; Grützmacher, PG; Guo, PY; Gutiérrez-Saborido, D; Habibi, M; Hall, MD; Hayes-Ryan, D; He, ZZ; Henderson, MJ; Herrick, JS; Herrmann, H; Hoang, Y; Hofmann, W; Hollingshead, M; Houlden, H; Hu, L; Huang, B; Huang, Y; Hussain, M; Huynh, HP; Iansa, P; Ivanenkov, YA; Jadhav, A; Jalaludin, B; Jalava, P; Karavadhi, S; Karpasas, M; Katahara, S; Kawel-Boehm, N; Khazanova, ES; King, JB; Klumpp-Thomas, C; Knibbs, LD; Komiya, Y; Komppula, M; Kranidiotis-Hisatomi, N; Krasnovskaya, OO; Kwiezinski, C; Lee, SW; Lee, TD; Leitner, W; Lerner, A; Leskinen, A; Li, B; Li, J; Li, Y; Li, Z; Liang, D; Liao, HB; Lima, JAC; Lin, L; Lin, W; Lin, Z; Liu, H; Liu, K; Liu, L; Liu, Q; Liu, Y; Lu, K; Luo, M; Ma, B; Machulkin, AE; Maimon, E; Majouga, AG; Márquez-Coello, M; Martinez, NJ; McCarthy, C; McIver, A; Meaney, S; Melotti, P; Menin, L; Mertes, S; Michael, S; Missert, JR; Moisy, P; Monda, KL; Mondello, P; Moore, WJ; Mücklich, F; Mues, KE; Muntner, P; Nahra, F; Navar, AM; Nelson, DJ; Nelson, RE; Ni, S; Nicotera, AG; Nimenko, EA; Nolan, SP; O'Donoghue, K; Oestreich, M; Pandey, RK; Pang, RD; Patnaik, S; Pei, W; Petrov, SA; Pevzner, S; Phillips, KS; Pintani, E; Pironti, E; Pokrovsky, VS; Polshakov, VI; Poudel, B; Pragani, R; Presser, V; Qu, H; Rahsepar, AA; Ramsey, MW; Ravotto, L; Ren, D; Ren, G; Ren, L; Rogach, AL; Rohde, JM; Roponen, M; Rosen, BD; Rosenkranz, A; Rosenson, RS; Salpietro, V; Saltykova, IV; Sato, T; Saveliev, OY; Senger, AR; Shafikov, RR; Shataer, D; Shen, M; Shi, Y; Shu, X; Simeonov, A; Skvortsov, DA; Slawin, AMZ; Smirnova, GB; Song, G; Stevens, VW; Stott, GM; Stratmann, F; Su, BJ; Suarez, S; Sugiyama, Y; Tabaczynski, W; Teo, KL; Tolosa, A; Totorika, A; Tracy, EC; Treggiari, D; Tridello, G; Troxler, T; Urban, DJ; Uspenskaya, AA; Vainer, R; Van Hecke, K; van Pinxteren, D; Vanden Broeck, SMP; Vanneman, ME; Vinogradov, SA; Wang, B; Wang, H; Wang, HS; Wang, L; Wang, R; Wang, X; Wang, YQ; Weller, C; Winkler-Heil, R; Xia, F; Xiao, F; Xin, XL; Xing, H; Xu, J; Xu, SL; Xu, Z; Yamane, M; Yamansarov, EU; Yan, T; Yang, BY; Yang, G; Yang, L; Yang, P; Yang, X; Yao, T; Yasgar, A; Ye, N; Yi, H; Yin, C; Yu, DYW; Yu, HY; Yu, J; Yuan, M; Zagefka, H; Zeng, XW; Zhang, H; Zhang, S; Zhang, W; Zhao, D; Zhao, W; Zhao, X; Zheng, H; Zheng, YK; Zhu, X; Zilbermann, I; Zyk, NU; Zyk, NV | 1 |
| Appenzeller, C; Bar, J; Cho, BC; Colinet, B; Gottfried, M; Gutierrez, V; Helland, A; Hung, JY; Johnson, ML; Komarnitsky, P; Laktionov, K; Lena, H; Luo, Y; Maag, D; Nickner, C; Okamoto, I; Rich, P; Sun, Z; Vajikova, A; van der Leest, C; Wolf, M; Zvirbule, Z | 1 |
| Arén Frontera, O; Bajars, M; Barlesi, F; Calabrò, L; de Marinis, F; Garassino, M; Ishii, H; Krzakowski, M; Lee, JS; Özgüroğlu, M; Park, K; Polychronis, A; Ruisi, M; Spigel, D; Szczesna, A; Uslu, R; Vansteenkiste, J; Xiong, H; Yang, JCH | 1 |
| Drapkin, BJ; Minna, JD | 1 |
| Feng, Y; Jiang, W; Kang, Y; Li, G; Li, J; Ma, H; Yu, X; Zhang, C | 1 |
| Xia, D; Xu, X; Yang, W; Zhang, Y | 1 |
| He, M; Liu, M; Liu, Q; Wei, Y; Xu, R; Yi, F; Zhang, W; Zhang, Y | 1 |
| Bearz, A; De Carlo, E; Del Conte, A; Schiappacassi, M; Stanzione, B | 1 |
| Cherry, DR; Courtney, PT; Kumar, A; Murphy, JD; Salans, MA; Yip, AT | 1 |
| Cao, K; Gao, Y; Gong, Y; Han, L; Jiang, X; Li, S; Luo, Y; Sun, W; Xie, C; Yuan, C | 1 |
| Ding, YJ; Feng, Y; Geng, YL; Ji, R; Le, VM; Ni, L; Xu, KD | 1 |
| Chen, L; Tang, H; Wang, Y; Yang, N; Zhang, Y | 1 |
| Cang, S; Chen, G; Cui, J; Du, Y; Fan, M; Fan, Y; Fang, J; Hu, C; Huang, D; Li, B; Li, J; Li, Y; Liu, L; Sun, P; Wang, S; Wang, Z; Wu, L; Xue, J; Yang, Z; Zhang, L; Zhang, W; Zhao, H; Zhou, C; Zhou, H; Zhou, J | 1 |
| Butkiewicz, D; Gdowicz-Kłosok, A; Giglok, M; Krześniak, M; Marszałek-Zeńczak, M; Suwiński, R | 1 |
| Chang, CC; Chen, HF; Chen, SC; Hung, HW; Liu, CY | 1 |
| Aomori, T; Arami, T; Egami, S; Fukunaga, K; Hashimoto, H; Ikemura, S; Kawada, I; Kawazoe, H; Nakada, H; Nakamura, T; Ohe, Y; Sakiyama, N; Soejima, K; Uozumi, R; Yamaguchi, M; Yasuda, H | 1 |
| Hao, X; Li, J; Lin, L; Xing, P; Xu, Z | 1 |
| Awad, MM; Cheng, Y; Garassino, MC; Kopp, HG; Kowalski, DM; Kurata, T; Langer, CJ; Lin, J; Paz-Ares, L; Pietanza, MC; Piperdi, B; Powell, SF; Rodríguez-Abreu, D; Rodríguez-Cid, J; Tafreshi, A; Zhao, B | 1 |
| Andric, Z; Barrios, CH; de Marinis, F; Enquist, I; Felip, E; Giaccone, G; Herbst, RS; Jassem, J; Kim, YC; Komatsubara, K; Kuriki, H; McCleland, M; Mocci, S; Morise, M; Oprean, C; Phan, S; Spigel, DR; Vergnenegre, A; Villalobos, M | 1 |
| Ding, D; Hu, H; Huang, J; Li, S; Liao, M; Liu, A; Liu, J; Shi, Y; Tian, X; Zhu, Y | 1 |
| Bi, M; Cang, S; Chen, G; Fang, J; Fang, W; Feng, J; Han, B; He, Z; Li, B; Li, J; Li, W; Lu, Y; Ma, R; Mancao, C; Mei, X; Peng, B; Puig, O; Ren, X; Song, Y; Sun, J; Sun, L; Wang, S; Wang, Z; Xu, W; Yang, Y; Yang, Z; Yu, Q; Zhang, L; Zhou, H; Zhou, J; Zhou, R | 1 |
| Guo, D; Huang, X; Li, H; Li, Z; Liu, T; Mi, Y; Xiao, Z; Xin, Y; Yang, S; Zhao, L; Zhao, W | 1 |
| Aredo, JV; Das, MS; Neal, JW; Padda, SK; Ramchandran, KJ; Shah, MP; Wakelee, HA | 1 |
| Chen, H; Feng, J; Gu, X; Gu, Y; Zhang, Y | 1 |
| Pathak, R; Salgia, R | 1 |
| Gu, D; Huang, P; Li, M; Lin, S; Luo, S; Rao, X; Wang, C; Weng, X; Xu, X | 1 |
| Chang, GR; Chen, CM; Chen, W; Chong, KY; Cidem, A; Lin, CH; Staniczek, T; Tsai, YT; Wang, JL; Yen, CC | 1 |
| Awad, MM; Zou, T | 1 |
| Hisada, T; Imai, H; Kaira, K; Kotake, M; Minato, K; Miura, Y; Mori, K; Saito, R; Sakurai, R; Tomizawa, Y | 1 |
| Ding, C; Guo, H; Guo, W; Guo, Y; He, Y; Hu, X; Lee, SH; Lei, QY; Li, S; Li, X; Ma, Y; Ning, F; Song, X; Xu, W; Zhang, Y; Zhao, Y | 1 |
| Han, ZG; Shan, L; Tao, J; Yu, TT | 1 |
| Luo, Y; Wang, BY; Zhang, QS | 1 |
| Dong, LX; Fu, BH; Li, XF; Liu, GF; Yu, SN; Zhang, SH | 1 |
| Gao, H; He, K; Li, X; Liu, X; Qin, H; Tang, C; Wang, H; Wang, W; Xu, B; Yang, S; Zhao, G | 1 |
| Gao, H; He, K; Li, L; Li, X; Liu, X; Qin, H; Qu, L; Tang, C; Wang, L; Wang, W; Xu, B; Yang, L | 1 |
| Ren, X; Wang, J; Wei, F; Xiong, Y; Zhao, N; Zheng, Y | 1 |
| Ahmad, A; Jan, AU; Qipeng, Y; Rahman, AU; Raza, M; Tahir, K; Ullah, S; Wang, A | 1 |
| Cui, JJ; Gong, WJ; Liu, ZQ; Wang, LY; Yin, JY; Zhou, HH; Zhu, T | 1 |
| Jin, YX; Li, X; Liu, ZQ; Qiu, CF; Tan, LM; Yin, JY; Zhang, W; Zhou, HH; Zhu, T | 1 |
| Bottone, MG; Gabano, E; Gallina, A; Gandin, V; Marzano, C; Osella, D; Rangone, B; Ravera, M; Tinello, S; Zanellato, I | 1 |
| Goto, A; Horita, N; Ito, K; Kaneko, T; Nagashima, A; Nakashima, K; Shibata, Y; Yamanaka, T | 1 |
| Behera, D; Lawania, S; Sharma, S; Singh, N | 1 |
| Agarwal, KK; Bhalla, AS; Das, CJ; Kumar, R; Mohan, A; Pandey, AK; Patel, CD; Sekhar Bal, C; Sharma, A; Sharma, MC; Sharma, P; Vishnubhatla, S | 1 |
| Kasahara, K; Sone, T; Tambo, Y | 1 |
| Chang, DW; Heymach, JV; Huang, M; Roth, JA; Shen, J; Wu, X; Ye, Y; Zhao, H | 1 |
| Agarwal, JP; Bhargava, P; Janu, A; Joshi, A; Kapoor, A; Mahajan, A; Noronha, V; Patil, VM; Prabhash, K; Zanwar, S | 1 |
| Bijwaard, K; Blumenthal, GM; Donoghue, M; Fan, I; Fiero, MH; Goldberg, KB; Keegan, P; Larkins, E; Lee, EY; Mathieu, L; McKee, A; Odogwu, L; Pazdur, R; Philip, R; Rodriguez, L | 1 |
| Andersohn, F; Bodnar, C; Hoyle, C; Mann, H; Mitsudomi, T; Mok, TSK; Yang, JC | 1 |
| Sawada, S; Sugimoto, R; Ueno, T; Yamashita, M | 1 |
| Pan, Z; Shen, Q; Shen, Y; Sun, K; Wang, Y; Zhang, X; Zhang, Z; Zhao, J; Zheng, J; Zhou, J; Zhu, Y | 1 |
| Gong, Y; Li, C; Li, Z; Lin, X; Liu, X; Luo, Y; Ma, S; Miao, H; Quan, H; Sun, Y; Tang, F; Tian, X; Wang, F; Wang, H; Xiao, Y; Xie, C; Yang, C; You, C; Yu, H; Zhang, J; Zhang, L | 1 |
| Gong, P; Ma, D; Ma, X; Wang, Y; Wei, Y | 1 |
| Antonio, M; Arnaiz, MD; Aso, S; Borràs, JM; Brao, I; Cardenal, F; González-Barboteo, J; Linares, J; Nadal, E; Navarro, A; Navarro, V; Padrones, S; Palmero, R; Ruffinelli, JC; Saldaña, J | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, BS; Kim, HG; Lee, KH; Lee, SH; Min, YJ; Park, K; Sun, JM; Yi, SY; Yun, HJ | 1 |
| Akamatsu, H; Hida, T; Hodge, RA; Imamura, F; Katakami, N; Kato, T; Kim, YH; Okamoto, I; Shinkai, M; Uchida, H | 1 |
| Hamada, N; Nakanishi, Y; Okamoto, I; Otsubo, K | 1 |
| Wang, Y; Xu, F; Xu, H; Ying, J; Zhu, W | 1 |
| Si, X; Wang, H; Wang, M; Wu, S; Zeng, X; Zhang, L; Zhang, X | 1 |
| Bonta, M; Holzlechner, M; Limbeck, A; Lohninger, H; Marchetti-Deschmann, M | 1 |
| Chen, J; Li, XP; Li, YQ; Yin, JY; Zhang, XY | 1 |
| Ajazi, E; Crawford, J; Johnston, MAM; Kinsey, E; Wang, X | 1 |
| Ahn, S; Jang, JS; Kim, JH; Kim, SH; Kim, YJ; Lee, H; Lee, JH; Lee, JS; Lee, YG | 1 |
| Alamgeer, M; Barrow, R; Boolell, V; Burgess, A; Cain, JE; Chin, V; Croucher, DR; de Kretser, DM; Ganju, V; Gonzalez-Rajal, A; Han, JZR; Harrison, CA; Hastings, JF; Hedger, MP; Jayasekara, WSN; Kita, B; Kostyrko, K; Kumar, B; Lee, HC; Lorensuhewa, N; Marini, KD; Marquez, C; Martelotto, LG; McCloy, RA; Oakes, SR; Robinson, BW; Rossello, FJ; Sweet-Cordero, EA; Szczepny, A; Vaghjiani, V; Watkins, DN; Waugh, T; Wu, J | 1 |
| Ardito, R; Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Conti, B; Ghidini, A; Ghilardi, M; Petrelli, F | 1 |
| Gandhi, L | 1 |
| Cao, S; Jin, S; Meng, Q; Wang, C; Xu, S; Yu, Y | 1 |
| Barbie, DA; Humeniuk, R; Kawashima, J; Kelly, K; Koczywas, M; Kong, S; Spira, A | 1 |
| Calabuig-Fariñas, S; Camps, C; Carreras, A; de Cid, R; Duran, X; Galván-Femenía, I; Guindo, M; Jantus-Lewintre, E; Kohno, T; Mercader, JM; Perucho, M; Ramirez, JL; Rosell, R; Sumoy, L; Torrents, D; Yokota, J | 1 |
| Karachaliou, N; Rosell, R | 1 |
| Abuodeh, YA; Dilling, TJ; Grass, GD; Naghavi, AO; Perez, BA | 1 |
| Goldberg, SB; Herbst, RS | 1 |
| Bang, SM; Chung, JH; Kim, JH; Kim, JW; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, JY; Lee, KS; Lee, KW; Shin, J; Suh, KJ | 1 |
| Chen, D; Fu, L; Guo, D; Jing, W; Kong, L; Li, M; Yu, J; Yue, J; Zhu, H | 1 |
| Hu, DL; Liu, YB; Mei, Y; Zhou, HH | 1 |
| Akamatsu, H; Chang, GC; Delmonte, A; Huang, X; Jenkins, S; John, T; Lee, JS; Su, WC; Wu, YL | 1 |
| Anai, S; Iwama, E; Nakanishi, Y; Okamoto, I; Otsubo, K; Tanaka, K; Yoneshima, Y | 1 |
| B, H; Das, HS; Dubey, RD; Dutta, PK; Goyal, R; Gupta, N; Kumari, S; Mandal, SK; Pandey, M; Paulraj, J; Samarla, M; Sarkar, A; Sarkar, S; Sengupta, A; Sharma, R; Sravanti, L; Vijaykumar, G | 1 |
| Garon, EB; Lisberg, A | 1 |
| Fujio, T; Kenmotsu, H; Kobayashi, H; Murakami, H; Naito, T; Nakashima, K; Omori, S; Ono, A; Takahashi, T; Wakuda, K | 1 |
| Gong, WJ; Han, Y; Hu, L; Huang, DD; Huang, H; Liu, RJ; Lv, YN; Ma, LY; Shi, SJ; Wu, SL; Xu, JQ; Zhang, Y | 1 |
| Banfi, D; Dyson, PJ; Kuttler, F; Turcatti, G; Varbanov, HP | 1 |
| Archila, P; Arrieta, O; Bacon, L; Báez, R; Campos Gómez, S; Cardona, AF; Carranza, H; Chirinos, L; Corrales, L; Cuello, M; de Lima, VCC; Freitas, HC; González, L; Granados, ST; Karachaliou, N; Martín, C; Mas, L; Núñez Cerrillo, G; Oblitas, G; Otero, J; Pérez, MA; Ramírez-Tirado, LA; Remolina Bonilla, YA; Rodriguez, J; Rojas, L; Rosell, R; Ruiz-Patiño, A; Trejo-Rosales, R; Vargas, C; Zatarain-Barrón, ZL | 1 |
| Arnaiz, MD; Aso, S; Bergamino, M; Brao, I; Cardenal, F; Montanya, E; Nadal, E; Navarro, A; Padrones, S; Palmero, R; Peiró, I; Ruffinelli, JC; Rullan, AJ; Saigí, M | 1 |
| Chen, JN; Feng, T; Li, HM; Lin, DX; Ma, F; Tan, W; Xu, BH; Yang, J; Yin, LL; Yuan, P | 1 |
| Aasheim, LB; Abrahamsen, TW; Davidson, B; Dybdahl, B; Flatmark, K; Fromm, B; Hovig, E; Julsrud, L; Kristensen, AT; Larsen, SG; Lund-Andersen, C; Nakken, S; Nygård, S | 1 |
| Cao, W; Chen, J; Chen, X; Ge, L; Ling, X; Ma, M; Tan, J; Wu, J; Xiong, F | 1 |
| Ameshima, S; Anzai, M; Ishizuka, T; Kadowaki, M; Kiyono, Y; Mori, T; Morikawa, M; Okazawa, H; Shigemi, H; Tsujikawa, T; Umeda, Y; Waseda, Y | 1 |
| Germonpré, P; Van den Wyngaert, T | 1 |
| Alewine, C; Calzone, K; Churpek, JE; Desai, A; Gadiraju, M; Gao, S; Gulsuner, S; Hassan, R; Hesdorffer, M; Khan, J; Kindler, HL; King, MC; Lee, MK; Mian, I; Morrow, B; Padiernos, E; Panou, V; Patel, S; Raffeld, M; Schrump, DS; Steinberg, SM; Thomas, A; Walsh, T; Wei, JS; Xi, L; Zhang, J | 1 |
| Gaillard, VE; Gessner, C; Linck, D; Losem, C; Metze, H; Tessen, HW; Zahn, MO | 1 |
| Becker, DJ; Brahmer, JR; Ettinger, DS; Levy, BP; Marrone, KA; Parikh, AB | 1 |
| Ahn, JS; Ahn, MJ; Lee, B; Lee, H; Lee, SH; Park, K; Park, S; Park, WY; Sun, JM | 1 |
| Choi, J; Grant, K; Mayo, J; McGuire, AL; Sedlic, T; Vieira, A; Yee, J | 1 |
| Daignault-Newton, S; Hough, S; Kalemkerian, GP; Reddy, HG; Weis, TM | 1 |
| Baglivo, S; Bellezza, G; Brambilla, M; Chiari, R; Cortellini, A; Crinò, L; De Giglio, A; Ficorella, C; Ludovini, V; Metro, G; Ricciuti, B; Sidoni, A | 1 |
| Dobrucka, R; Kaczmarek, M; Romaniuk-Drapała, A | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Bonanno, L; Costa, C; Favaretto, A; Majem, M; Rosell, R; Rugge, M | 1 |
| Bai, CX; Chen, HY; Chen, YY; Gao, ZQ; Han, BH; Jin, L; Lu, DR; Peng, J; Qian, J; Wang, HJ; Wang, JC; Wu, WT; Yang, J; Yang, LX; Zhao, XY | 1 |
| Akamatsu, H; Inoue, A; Kobayashi, K; Mitsudomi, T; Mori, K; Nakagawa, K; Nakanishi, Y; Nukiwa, T; Yamamoto, N | 1 |
| Gao, G; He, Y; Li, X; Ren, S; Zhou, C; Zhou, F | 1 |
| Li, Y; Li, Z; Lu, L; Xie, X; Xiong, T | 1 |
| Blackstock, AW; Bogart, JA; Crawford, J; Hodgson, L; Pang, H; Salama, JK; Schild, SE; Urbanic, JJ; Vokes, EE | 1 |
| Liu, LX; Shen, H; Shu, YQ; Xu, TP | 1 |
| Fang, WF; Guo, Y; Hu, ZH; Huang, Y; Ma, YX; Wu, X; Xue, C; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, YY | 1 |
| Levy, B; Saxena, A; Schneider, BJ | 1 |
| Ganti, AK; West, WW; Zhen, W | 1 |
| Akca, Z; Aksahin, A; Aslan, T; Berk, V; Buyukcelik, A; Erden, A; Karaca, H; Mutlu, H; Ozkan, M | 1 |
| Ardine, M; Barni, S; Cabiddu, M; Coinu, A; Ghilardi, M; Petrelli, F | 1 |
| Nørøxe, DS; Sørensen, JB; Wallerek, S | 1 |
| Lin, ZF; Lu, FZ; Shen, XY; Wu, Y; Zhao, LT | 1 |
| Eberhardt, WE; Gauler, TC; Hoffmann, AC; Nel, I; Nickel, AC; Schuler, M; Thomale, J | 1 |
| Eaddy, M; Green, MR; Gruschkus, SK; Peterson, P; Shah, M; Winfree, KB | 1 |
| Chudziak, D; Ciesielka, M; Homa, I; Kalinka-Warzocha, E; Kozioł, P; Krawczyk, P; Kucharczyk, T; Milanowski, J; Mlak, R; Ramlau, R; Wasylecka-Morawiec, M; Wojas-Krawczyk, K | 1 |
| Jiang, L; Yan, B; Zhang, W | 1 |
| Fiolitaki, G; Georgoulias, V; Koutsopoulos, A; Mavroudis, D; Stathopoulos, E; Vassalou, H; Voutsina, A | 1 |
| Ding, ZY; Liu, YM; Wang, C; Zhou, L | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, L; Xu, X | 1 |
| Hao, X; He, P; Hu, X; Li, J; Shi, Y; Wang, B; Wang, H; Wang, Y; Wang, Z; Yang, S; Yu, S; Zhang, X | 1 |
| Ding, X; Hu, J; Jiang, F; Qiu, M; Xu, L; Yang, X; Yin, R | 1 |
| Bellezza, G; Bennati, C; Cenci, M; Chiari, R; Crinò, L; Ferolla, P; Flacco, A; Giannarelli, D; Ludovini, V; Metro, G; Minotti, V; Puma, F; Rebonato, A; Ricciuti, B | 1 |
| Chen, X; Gong, Y; He, J; Xia, J; Zhu, N | 1 |
| Cai, Y; Chen, H; Gao, Z; Han, B; Jiang, G; Li, X; Lu, D; Qian, J; Su, B; Tan, X; Wang, J; Wang, S; Wu, Q; Yang, Y; Zhao, X | 1 |
| Hu, N; Liu, Y; Wu, F; Zhang, J; Zheng, Y | 1 |
| Du, XJ; Li, YP; Liu, Y; Liu, YZ; Wang, J; Yang, XZ; Zhu, YH | 1 |
| Xian, L; Yang, Y | 1 |
| Boikos, SA; Brahmer, JR; Ettinger, DS; Forde, PM; Giaccone, G; Hann, CL; Hooker, CM; Illei, PB; Kelly, RJ; Petrini, I; Rudin, CM; Yang, SC | 1 |
| Araújo, A; Coelho, A; Lima, A; Martins, S; Medeiros, R; Seabra, V | 1 |
| Hu, W; Pan, J; Yang, G; Yang, S; Zhao, P | 1 |
| Jin, ZY; Wang, Y; Xu, SF; Yue, WT; Zhang, LN; Zhao, XT | 1 |
| Cai, R; Liu, T; Lu, D; Wang, W; Wu, H; Zhuang, X | 1 |
| Ji, F; Li, J; Liu, J; Wang, B; Wu, G | 1 |
| Jiang, X; Wang, X; Wu, W; Yang, C; Zhang, Y; Zhen, X | 1 |
| Bilgin, E; Duranyildiz, D; Karabulut, S; Tas, F | 1 |
| Chen, J; Gong, WJ; Gong, ZC; He, H; Li, F; Li, X; Li, XP; Liu, ZQ; Qian, CY; Wang, Y; Xiao, L; Yin, JY; Yin, T; Zhang, Y; Zheng, Y; Zhou, BT; Zhou, HH | 1 |
| Yuan, X; Yuan, Y; Zhang, Z; Zhao, X | 1 |
| Ball, DL; Chabrot, M; Everitt, SJ; Hicks, RJ; Leimgruber, A; MacManus, M; Möller, A; Solomon, B | 1 |
| Allard, A; Bennouna, J; Chadjaa, M; Gorbounova, V; Grossi, F; Kowalski, DM; Reck, M; Rey, A; von Pawel, J | 1 |
| Baty, F; Betticher, DC; Brauchli, P; Brutsche, M; Droege, C; Früh, M; Gautschi, O; Joerger, M; Klingbiel, D; Ochsenbein, A; Pless, M; Rothschild, S; Stahel, RA; von Moos, R; Zappa, F | 1 |
| Alexandris, E; Arrieta, O; Bidoli, P; Cappuzzo, F; Ciuleanu, TE; Czyzewicz, G; Dakhil, S; Gans, S; Garon, EB; Goksel, T; Gorbunova, V; Grigorescu, A; Karaseva, N; Kim, JH; Kowalyszyn, RD; Lewanski, CR; Orlov, SV; Park, K; Pérol, M; Pikiel, J; Prabhash, K; Reck, M; Sashegyi, A; Syrigos, KN; Thomas, M; Yurasov, S | 1 |
| Han, B; Jin, B; Lu, D; Niu, Y; Shao, M; Ye, J | 1 |
| Dyszkiewicz, W; Kalinka-Warzocha, E; Kałakucka, K; Knetki-Wróblewska, M; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Powrózek, T; Ramlau, R; Winiarczyk, K; Wojas-Krawczyk, K | 1 |
| Kang, YM; Lin, DJ; Liu, QH; Tian, GY; Wan, YY; Yang, SX; Yao, F; Yao, ZH | 1 |
| Mellema, WW; Postmus, PE; Smit, EF; van der Hoek, D | 1 |
| Fábián, K; Furák, J; Gyulai, M; Losonczy, G; Moldvay, J; Pápay, J; Podmaniczky, E; Puskás, R; Tímár, J; Tiszlavicz, L | 1 |
| Georgoulias, V; Giagkas, G; Ioannidis, G; Koutsopoulos, A; Lagoudaki, E; Mavroudis, D; Papadaki, C; Sfakianaki, M; Souglakos, J; Trypaki, M; Tsakalaki, E; Voutsina, A | 1 |
| Choi, CM; Chung, JH; Hwang, YI; Jang, SH; Jo, J; Kim, CH; Kim, HR; Kim, SS; Kim, WS; Koh, JS; Lee, JC; Park, TS; Yoon, HI | 1 |
| Hao, K; Hu, H; Sheng, Z; Wang, Q; Xu, C; Yan, J; Yu, L | 1 |
| Bierbach, U; Ding, S; Kucera, GL; Pickard, AJ | 1 |
| Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q | 1 |
| Chen, J; Li, X; Liu, J; Liu, Z; Qian, C; Wang, Y; Wang, Z; Xiao, L; Yin, J; Zhang, W; Zheng, Y; Zhou, H; Zou, T | 1 |
| Chen, Q; Ding, L; Gao, H; Hong, X; Jiang, Z; Liang, Y; Liu, K; Wu, H; Zhou, N | 1 |
| Endoh, S; Fujita, K; Hagihara, Y; Horie, M; Iwahashi, H; Kato, H; Kinugasa, S; Komaba, LK; Miyauchi, A; Nakamura, A; Nishio, K; Yamamoto, K; Yoshida, Y | 1 |
| Chen, J; Chen, W; Chen, Y; Hu, C; Li, X; Luo, Z; Rajan, N; Wang, Y; Wu, S; Yang, Y | 1 |
| Amieva-Rivera, E; Arrieta, O; Astudillo, H; Campos-Parra, AD; Cardona, AF; Carranza, H; Corrales, L; Karachaliou, N; Otero, J; Rodríguez, J; Rosell, R; Sánchez-Reyes, R; Vargas, C | 1 |
| Cai, R; Fan, Y; Hong, R; Li, Q; Ma, F; Shi, X; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Fang, C; Fu, Z; Jiang, H; Li, J; Lu, Q; Pei, Z; Wang, E; Wang, H; Wang, J; Wang, S | 1 |
| Aakre, JA; Johnson, C; Loprinzi, CL; Pankratz, VS; Staff, NP; Velazquez, AI; Windebank, AJ; Yang, P | 1 |
| Agelaki, S; Georgoulias, V; Kalikaki, A; Kotsakis, A; Koutsopoulos, A; Mavroudis, D; Papadaki, C; Sfakianaki, M; Souglakos, J; Voutsina, A; Xyrafas, A; Yachnakis, E | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, JS; Kim, KH; Kim, SH; Kim, TM; Kim, YJ; Lee, JS; Lee, SH; Park, S | 1 |
| Zhao, YQ; Zou, HZ | 1 |
| Choi, YS; Jo, DY; Kim, S; Lee, HJ; Lee, MW; Moon, JY; Ryu, HW; Song, IC; Yang, YJ; Yun, HJ | 1 |
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Bronte, G; Cajozzo, M; Fiorentino, E; Gil-Bazo, I; Lequaglie, C; Passiglia, F; Pauwels, P; Rizzo, S; Rolfo, C; Russo, A; Santini, D; Van Meerbeeck, JP | 1 |
| Gao, H; Guo, W; Li, J; Li, X; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Xu, J; Yang, H; Yang, L | 1 |
| Chen, YM; Lee, YC; Lin, YH; Perng, RP; Tseng, YC; Tseng, YH; Whang-Peng, J | 1 |
| Hata, A; Hattori, Y; Imamura, F; Kaneda, T; Katakami, N; Kumagai, T; Morita, S; Negoro, S; Nishimura, T; Nishino, K; Okuda, C; Satouchi, M; Tachihara, M; Urata, Y; Yokota, S | 1 |
| Cao, S; Dai, J; Hu, Z; Ma, H; Shen, H; Shen, W; Shu, Y; Wang, C; Xu, L; Yin, R; Zhu, M | 1 |
| Fujita, H; Horita, N; Ishigatsubo, Y; Kaneko, T; Kudo, M; Moriyama, Y; Shinkai, M; Yamanaka, T | 1 |
| Chen, W; Fang, Y; Feng, JG; Li, ZP; Mao, WM; Su, D; Xu, XL; Zhang, YP | 1 |
| Barker, SS; Borghaei, H; Obasaju, C; Stinchcombe, TE; Treat, JA | 1 |
| Ames, T; Blanco, E; Corte-Rodríguez, M; Espina, M; Montes-Bayón, M; Sanz-Medel, A; Sierra, LM | 1 |
| Bettini, A; Bonomi, L; Broggini, M; Caiola, E; Fabbri, MA; Farina, G; Floriani, I; Ganzinelli, M; Garassino, MC; Lauricella, C; Longo, F; Macerelli, M; Marabese, M; Marsoni, S; Piva, S; Rulli, E; Shepherd, FA; Veronese, S | 1 |
| Felley-Bosco, E; Friess, M; Frischknecht, L; Korol, D; Opitz, I; Soltermann, A; Stahel, R; Thies, S; Vrugt, B; Weder, W | 1 |
| Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
| Han, Y; Hu, R; Jiao, Y; Li, J; Weng, Q; Yuan, Z | 1 |
| Baha, A; Ozturk, C; Yıldırım, F; Yurdakul, AS | 1 |
| Li, C; Li, M; Li, Q; Peng, Y; Qing, Y; Ren, T; Shan, J; Wang, D; Wang, G; Wang, L; Yang, Z; Zhang, S | 1 |
| Chen, J; Dai, Y; Fei, X; Pan, Q; Shi, P; Shi, X; Tao, X; Wang, C; Yang, Y; Zhou, H; Zhu, L | 1 |
| Aerts, JG; de Castro Carpeño, J; Dyachkova, Y; Girvan, A; Kraaij, K; Lesniewski-Kmak, K; Moro-Sibilot, D; Nacerddine, K; Schnabel, PA; Smit, E; Smith, KT; Villatoro, R; Visseren-Grul, C | 1 |
| Benkli, K; Bostancioğlu, RB; Kaya, M; Koparal, AT | 1 |
| Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W | 1 |
| Arrieta, O; Cappuzzo, F; Carter, GC; Ciuleanu, TE; Dakhil, S; Garon, EB; Goksel, T; Karaseva, N; Kim, JH; Kowalyszyn, RD; Lee, P; Lewanski, CR; Park, K; Pérol, M; Pikiel, J; Prabhash, K; Reck, M; Syrigos, KN; Thomas, M; Yurasov, S; Zimmermann, A | 1 |
| Kijima, T; Minami, T; Morio, K; Niki, K; Sozu, T; Uejima, E | 1 |
| Liu, Y; Wang, L; Yang, P; Zhou, Y | 1 |
| Beck, SL; Brown, S; Kolb, NA; Mooney, K; Singleton, JR; Smith, AG; Stoddard, GJ | 1 |
| Choi, SI; Hur, GY; In, KH; Jung, WJ; Kang, KH; Kim, CH; Kim, JH; Lee, EJ; Lee, JS; Lee, SH; Lee, SY; Min, KH; Shim, JJ; Shin, C | 1 |
| Brantley, SG; Cress, WD; Gray, JE; Haura, EB; Jhuraney, A; Kinose, F; Koomen, JM; Kroeger, JL; Monteiro, AN; Remily-Wood, E; Rix, L; Rix, U; Woods, NT; Wright, G | 1 |
| Chen, J; Cui, J; Jiang, W; Liu, Z; Wang, Z; Yin, J; Zheng, W; Zhou, H; Zou, T | 1 |
| Chen, SH; Cheng, L; Fan, L; Guo, Y; Hu, L; Lv, QL; Qin, CZ; Qu, Q; Sun, B; Zhou, HH | 1 |
| Hirose, T; Kusaka, K; Matsui, H; Mori, A; Ohta, K; Tamura, A | 1 |
| Fuerte, F; Klughammer, B; Ladrera, G; Lee, JS; Mok, T; Perez-Moreno, P; Sandoval-Tan, J; Shames, DS; Srimuninnimit, V; Sriuranpong, V; Thongprasert, S; Truman, M; Wu, YL; Yu, CJ | 1 |
| Bonomi, L; Caiola, E; Ganzinelli, M; Marabese, M; Piva, S; Rulli, E | 1 |
| Enatsu, S; Ferry, D; Hosomi, Y; Kasahara, K; Koue, T; Lee, P; Nakagawa, K; Nakamura, T; Nishio, M; Ohe, Y; Takahashi, T; Tamura, T; Yamada, K; Yamamoto, N; Yoh, K | 1 |
| Baugh, L; Chen, C; Dai, N; Guan, W; He, L; Jin, F; Li, M; Qing, Y; Shan, J; Tell, G; Wang, D; Wang, H; Wilson, DM; Yang, X; Yang, Y; Zhang, S; Zhong, Z | 1 |
| Ahn, MJ; Cho, BC; Jang, JS; Jung, I; Kim, DW; Kim, HR; Kim, JH; Kim, SW; Lee, DH; Lee, KH; Sun, JM | 1 |
| Chen, L; Ding, J; Li, J; Li, N; Ma, H; Sun, Y; Wang, C; Xiao, Z; Yao, X | 1 |
| Postel-Vinay, S; Soria, JC | 1 |
| Baracos, V; Bristow, C; Crosby, V; D'Souza, C; Hennig, I; Hussain, A; O'Connor, R; Potter, V; Proffitt, A; Wilcock, A | 1 |
| Ahn, M-J; Akamatsu, H; Garassino, MC; Ghiorghiu, S; He, Y; Kim, HR; Lee, CK; Mann, H; Marotti, M; Mok, TS; Papadimitrakopoulou, VA; Ramalingam, SS; Sebastian, M; Shepherd, FA; Templeton, A; Theelen, WS; Wu, Y-L | 1 |
| Broggini, M; Caiola, E; Ceppi, L; Damia, G; Ganzinelli, M; Garassino, MC; Guffanti, F; Marabese, M; Piva, S; Rulli, E | 1 |
| Li, B; Li, W; Ma, K; Su, K; Wang, C; Xu, W | 1 |
| Berghmans, T; Biesma, B; Chittazhathu Kurian Kuruvilla, Y; Ciardiello, F; Coate, L; Cobo Dols, M; Collado Martin, R; Cuffe, S; Curioni-Fontecedro, A; Dafni, U; de Hosson, S; Garde Noguera, J; Gasca-Ruchti, A; Gautschi, O; Gregorc, V; Groen, HJM; Horgan, A; Insa, A; Juan Vidal, Ó; Kassapian, M; Láng, I; López Martín, A; Mark, MT; Massutí, B; Meldgaard, P; Novello, S; Palmero Sanchez, R; Peralta, S; Peters, S; Pieterman, R; Ponce Aix, S; Rauch, D; Smit, EF; Stahel, RA; Summers, Y; Torri, V; Tsourti, Z; van den Berg, PM; van Heemst, R; van Henten, AMJ; Villa Guzmán, JC; Zielinski, CC | 1 |
| Fu, LW; To, KK; Tong, WS | 1 |
| Hutchinson, L | 1 |
| Antonio, BS; Bunn, PA; Ciuleanu, T; Denne, J; Iturria, N; John, W; Paz-Ares, LG; Scagliotti, GV; Zimmermann, A | 1 |
| Ishida, H; Kaneko, K; Kobayashi, K; Nitanda, H; Sakaguchi, H; Yamazaki, N | 1 |
| Zhang, J; Zhang, Y | 1 |
| Ding, X; Fei, K; Liu, D; Lu, Y; Su, B; Xu, W; Yang, Y | 1 |
| Pinion, S | 1 |
| Chen, IS; Kirn, D; Lee, JY; Lin, TK; Liu, TC; Tsao, CJ | 1 |
| Cho, JH; Jang, TW; Kim, CS; Kim, HJ; Kim, HT; Kim, SK; Kim, YH; Kwak, SM; Lee, JE; Ryu, JS; Shin, ES; Yoo, YK; Yun, MH | 1 |
| Dickgreber, NJ; Fink, TH; Hossain, AM; Latz, JE; Musib, LC; Thomas, M | 1 |
| Chu, Z; Gao, G; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Choi, JH; Choi, YW; Han, JH; Hwang, SC; Jeong, SH; Jung, JH; Kang, SY; Kim, JH; Lee, HW; Oh, YT; Park, KJ; Sheen, SS | 1 |
| Altug, S; Chu, DT; Cok, G; Damyanov, D; Hall, B; Hsu, HK; Kim, SW; Patil, S; Roubec, J; West, T | 1 |
| Crysandt, M; Esser, A; Jost, E; Osieka, R; von Hobe, S; Wilop, S | 1 |
| Hu, WJ; Liu, BR; Liu, XZ; Qian, XP; Shi, MQ; Wei, J; Zou, ZY | 1 |
| Adjei, AA; Baas, P; Choy, H; Gandara, DR; Gaspar, LE; Goss, G; Lara, PN; Saijo, N; Sangha, R; Schiller, JH; Vokes, EE | 1 |
| Ahn, RW; Chen, H; Krett, NL; O'Halloran, TV; Pazicni, S; Penner-Hahn, JE; Rosen, ST | 1 |
| Lu, S; Yu, YF; Zhang, YF | 1 |
| Chen, ZW; Lu, S; Zhang, YF | 1 |
| Gupta, A; Mittal, B; Natu, SM; Negi, MP; Prasad, R; Srivastava, AN; Srivastava, S | 1 |
| Cao, Y; Chen, B; Cheng, H; Cheng, L; Feng, J; Li, F; Sun, N; Sun, X | 1 |
| Guan, Y; Lin, D; Liu, Y; Liu, Z; Ott, J; Shen, Y; Wu, C; Xu, B; Yu, D; Yuan, P | 1 |
| Agelaki, S; Agelidou, A; Chandrinos, V; Georgoulias, V; Gioulbasanis, I; Hatzidaki, D; Karampeazis, A; Kotsakis, A; Lerikou, M; Papakotoulas, P; Polyzos, A; Tsiafaki, X; Ziras, N | 1 |
| Gou, Y; Guo, H; Jiang, L; Tian, J; Yang, K; Yang, Q; Zhang, L; Zhang, R | 1 |
| Diehn, M; Dieterich, S; Hong, JC; Kothary, N; Le, QT; Loo, BW; Maxim, PG; Rao, AK; Sze, DY; Yu, Y | 1 |
| Endo, M; Naito, T; Takahashi, T; Tamiya, A; Yamamoto, N | 1 |
| Aglione, S; Bareggi, C; Blackhall, F; Califano, R; Collovà, E; Farina, G; Fatigoni, S; Galetta, D; Gallerani, E; Garassino, MC; Ghidini, A; La Verde, N; Lo Dico, M; Lorigan, P; Mancuso, A; Martelli, O; Michetti, G; Rossi, A; Saggia, C; Thatcher, N; Torri, V | 1 |
| Eguchi, K; Ichinose, Y; Kishi, K; Minato, K; Nishikawa, M; Nogami, N; Okamoto, H; Seki, N; Seto, T; Shinkai, T; Takiguchi, Y; Watanabe, K | 1 |
| Hallahan, DE; Hariri, G; Lukehart, CM; Morris, WH; Wellons, MS | 1 |
| Berard, H; Bota, S; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Paillotin, D; Robinet, G; Thomas, P; Vergnenegre, A | 1 |
| Jiang, J; Li, L; Lin, Q; Tian, J; Wang, Q; Wang, X | 1 |
| Fan, Y; Huang, ZY; Luo, LH; Yu, HF | 1 |
| Heijmen, BJ; Hoogeman, MS; Levendag, PC; Nuyttens, JJ; van de Water, S; van der Holt, B; van der Voort van Zyp, NC | 1 |
| Murphy, M; Stordal, B | 1 |
| Daignault, S; Dy, GK; Gadgeel, SM; Kalemkerian, GP; Ramnath, N; Schneider, BJ; Wozniak, AJ | 1 |
| Baas, P; Beijnen, JH; Burgers, JA; Burylo, A; deJong, D; Huitema, AD; Joerger, M; Schellens, JH | 1 |
| Dong, ZZ; Feng, DY; Huang, Q; Liu, ZQ; Shen, J; Yin, JY; Zhang, JT; Zhong, MZ; Zhou, HH | 1 |
| Aakre, JA; Aubry, MC; Croghan, GA; Cunningham, JM; Johnson, C; Li, Y; Molina, J; Pankratz, VS; Sun, Z; Wampfler, JA; Wang, L; Wu, D; Yang, P | 1 |
| Bennouna, J; de Castro, J; Dingemans, AM; Gridelli, C; Griesinger, F; Grossi, F; Langer, C; Rossi, A; Thatcher, N; Wong, EK | 1 |
| Saijo, N | 1 |
| Douillard, JY; Jiang, GL; Kim, ES; Li, LY; Liao, ML; Milenkova, T; Sun, Y; Wu, YL | 1 |
| Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Hockenhull, J; Martin Saborido, C; Oyee, J; Ramani, VS | 1 |
| Georgoulias, V; Pallis, AG | 1 |
| Li, L; Wang, X; Xu, C; Zhang, Y | 1 |
| Alberola, V; Alfaro, V; Camps, C; Cobo, M; Dómine, M; Gutiérrez-Calderón, V; Isla, D; Lardelli, P; Massuti, B; Nieto, A; Provencio, M; Rosell, R; Tarón, M; Viñolas, N | 1 |
| Argiris, A; Ballas, MS; Belani, CP; Davies, A; Edelman, M; Gandara, DR; Gitlitz, BJ; Groshen, S; Hoffman, P; Koczywas, M; Liu, SV; Ramalingam, S; Tsao-Wei, DD; Vokes, EE | 1 |
| Du, X; Li, M; Liu, L; Lu, C; Shi, J; Sun, T; Tang, X; Xiao, L; Yang, M; Yu, D; Yuan, Q; Zhang, X; Zhang, Z | 1 |
| Li, LF; Li, W; Liu, XM; Qian, ZZ; Qiu, LH; Wang, HQ; Zhang, HL | 1 |
| Jaśkiewicz, P; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Winiarczyk, K; Wojas-Krawczyk, K | 1 |
| Cao, DD; Chen, Y; Ge, W; Jie, FF; Wang, HM; Zheng, YF | 1 |
| Chen, H; Fan, W; Gao, Z; Gu, S; Han, B; Jin, L; Lu, D; Qian, J; Tan, X; Wang, H; Wang, J; Wei, Q; Wu, Q; Wu, W; Zhang, W; Zhao, X | 1 |
| An, TT; Bai, H; Duan, JC; Liu, XH; Wang, J; Wang, SH; Wang, YY; Wang, ZJ; Wu, MN; Yang, L; Zhao, J; Zhuo, ML | 1 |
| Bierbach, U; Essader, AS; Kucera, GL; Levine, KE; Qiao, X; Wright, MW; Zeitany, AE | 1 |
| Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yi, JH; Yim, DS | 1 |
| Bian, B; Hu, N; Li, Y; Wu, F; Xu, G; Zheng, Y | 1 |
| Albert, I; Azzoli, CG; Bodkin, D; Iannotti, NO; Jiang, PY; Juhász, E; Kelly, K; Koutsoukos, T; Patel, JD; Pereira, JR; Weems, G; Zatloukal, P | 1 |
| Avila, J; Cortés, P; Gill, M; Pizarro, I; Rivera, L; Román, DA; Torres, C | 1 |
| Georgoulias, V; Giannousi, Z; Gioulbasanis, I; Kakalou, D; Makridou, M; Pallis, A; Perdikouri, IE; Vlachostergios, PJ; Xyrafas, A | 1 |
| Chang, GC; Chen, YM; Cheng, YK; Liao, WY; Shih, JY; Yang, JC; Yu, CJ | 1 |
| Bennis, R; Bruce, RH; Das, M; Frankel, P; Hsieh, HB; Liu, X; Ly, JC; Nieva, JJ; Riess, JW; Schwartz, E; Wakelee, HA; Zhou, L | 1 |
| Abedallaa, N; Baey, C; Besse, B; de Montpreville, VT; Fabre, D; Guigay, J; Pechoux, CL; Pignon, JP; Planchard, D; Soria, JC; Tremblay, L | 1 |
| Guo, S; Hu, J; Jin, L; Li, Q; Liu, J; Lu, D; Wang, JC; Wang, L; Wu, J; Ying, J; Zhao, N; Zhou, Y; Zou, H | 1 |
| Huang, Q; Liu, ZQ; Yin, JY; Zhao, YC; Zhou, HH | 1 |
| Chen, H; Chen, W; Fan, W; Gu, S; Han, B; Jin, L; Lu, D; Qian, J; Qu, HQ; Tan, X; Wang, H; Wang, J; Wang, Q; Wei, Q; Wu, J; Wu, Q; Wu, W; Yang, L; Yin, M; Zhao, X | 1 |
| He, J; Li, H; Lu, J; Ma, P; Qin, Y; Wang, J; Wei, L; Xu, J; Zhang, X | 1 |
| Chow, CW; Fujimoto, J; He, G; Kalhor, N; Kim, ES; Lee, JJ; Siddik, ZH; Stewart, DJ; Swisher, SG; Wistuba, II | 1 |
| Fandzloch, M; Muzioł, T; Sitkowski, J; Wietrzyk, J; Łakomska, I | 1 |
| Hu, J; Lu, FF; Shang, LH; Wei, HB; Wei, M; Yu, Y; Zhang, YY | 1 |
| Baldotto, C; Bennouna, J; Ciuleanu, TE; Goksel, T; Gorbunova, V; Le-Guennec, S; Miller, V; Novello, S; Ozguroglu, M; Ramlau, R; Rey, A; Scagliotti, G; Shepherd, FA; Thatcher, N | 1 |
| Hashemi-Sadraei, N; Pennell, NA | 1 |
| Cohen, J; Halm, EA; Mandeli, J; Mhango, G; Sigel, K; Strauss, G; Wisnivesky, J | 1 |
| Gao, G; Li, A; Li, X; Ren, S; Xu, J; Zhang, J; Zhang, L; Zhou, C | 1 |
| Hwang, YI; Jang, SH; Jung, KS; Kim, DG; Kim, JH; Kim, SY; Park, S | 1 |
| Guan, ZZ; Guo, Y; Huang, H; Jiang, WQ; Li, S; Liao, H; Yang, XQ; Zhan, J; Zou, BY | 1 |
| Duan, Z; He, C; Li, P; Xu, Q; Yuan, Y | 1 |
| Burgers, SA; Dingemans, AM; Groen, HJ; Heideman, DA; Kunst, PW; Mellema, WW; Smit, EF; Thunnissen, E; van Wijk, A | 1 |
| Correa, AM; Erasmus, JJ; Gold, KA; Heymach, J; Kalhor, N; Kim, ES; Lee, JJ; Munden, R; Papadimitrakopoulou, V; Pataer, A; Rice, DC; Swisher, SG; William, WN; Wistuba, II | 1 |
| Ji, L; Pei, Y | 1 |
| Delauter, BJ; Egorin, MJ; Eiseman, JL; Gervais, AC; Grim, A; Hamburger, DR; Joseph, E; Pluim, D; Potter, DM; Schellens, JH; Zamboni, WC; Zuhowski, EG | 1 |
| Glaspy, J; Poulsen, E; Rossi, G; Vansteenkiste, J | 1 |
| Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
| Greco, FA | 1 |
| Blay, P; Buesa, JM; Esteban, E; Estrada, E; Fernández, Y; Fra, J; Lacave, AJ; Mareque, B; Muñiz, I; Palacio, I; Sánchez, R; Uña, E; Vieitez, JM; Villanueva, N | 1 |
| Kim, CH; Kim, HT; Lee, JC; Park, YH; Ryoo, BY | 1 |
| Christiani, DC; Gurubhagavatula, S; Liu, G; Lynch, TJ; Neuberg, DS; Park, S; Su, L; Wain, JC; Zhou, W | 1 |
| Church, N; Clifton, JC; Coxson, H; English, J; Evans, K; Finley, RJ; Jangra, D; Lara-Guerra, H; Mayo, JR; Powell, TI; Yee, J | 1 |
| Albert, M; Becker, V; Franke, UF; Kaluza, M; Lessel, M; Roskos, M; Wahlers, T; Wittwer, T | 1 |
| Bak, JY; Bang, YJ; Choi, IS; Heo, DS; Kim, DW; Kim, JH; Kim, NK; Kim, SI; Kim, TY; Kim, YT; Kim, YW; Kwon, JH; Oh, DY; Park, CI; Park, SR; Sung, SW; You, CK | 1 |
| John, M; Kröncke, T; Liebers, U; Schmidt, B; Witt, C | 1 |
| Ackley, MC; Augustus, TM; Bierbach, U; Hess, SM; Mounce, AM; Sequeira, RC | 1 |
| Endo, K; Hatake, K; Ishikawa, T; Ishizaka, Y; Matsuyama, S; Mimura, H; Mori, Y; Nishino, Y; Nishio, K; Saito, A; Sakuma, T; Sano, Y; Shimura, M; Tamasaku, K; Terui, Y; Ueno, K; Yabashi, M; Yamamura, K; Yamauchi, K; Yumoto, H | 1 |
| Lin, DX; Miao, XP; Sun, Y; Tan, W; Wang, ZH; Xu, BH; Yuan, P; Zhang, XM | 1 |
| Guan, ZZ; Li, S; Xu, RH; Yuan, ZY | 1 |
| Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M | 1 |
| Ballas, MS; Dennis, PA | 1 |
| Brown, DB; Cai, SR; Fundakowski, CE; McLeod, HL; Strychor, S; Zamboni, WC | 1 |
| Kunitoh, H; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Belani, CP; Fidias, P; Fossella, F; Gorbounova, V; Kaukel, E; Mattson, KV; Millward, M; Pereira, JR; Pluzanska, A; Ramlau, R; Szczesna, A; von Pawel, J | 1 |
| Hotta, K; Kiura, K | 1 |
| Ahn, JS; Ahn, YC; Choi, YS; Kim, H; Kim, J; Kim, K; Park, BB; Park, JO; Park, K; Shim, YM | 1 |
| Horai, T; Kasahara, K; Nishio, M; Ohyanagi, F; Shibata, K; Shirosaki, H; Taguchi, F; Takeda, Y | 1 |
| Anderson, H; Lorigan, P; Margison, GP; Margison, JM; Martin, F; Ranson, M; Thatcher, N; White, SC | 1 |
| Lester, JF; Macbeth, FR | 1 |
| Chen, XZ; Gao, WQ; Hou, SQ; Liu, WP; Liu, Y; Lou, LG; Ye, QS; Yu, Y | 1 |
| Gadgeel, SM; Heath, EI; Heilbrun, LK; Ruckdeschel, JC; Venkatramanamoorthy, R; Wozniak, A | 1 |
| Mountzios, G; Olaussen, KA; Soria, JC | 1 |
| Edelman, MJ; Lustberg, MB | 1 |
| Jett, JR; Keith, RL; Kesler, KA; Schild, SE | 1 |
| Duarte, RL; Luiz, RR; Paschoal, ME | 1 |
| Belani, C; Ramalingam, S | 1 |
| Barlési, F; Breen, D | 1 |
| Lee, R; Leighl, NB; Loreto, M; Ng, R | 1 |
| Donohue, JP; Einhorn, LH; Williams, SD | 1 |
| Henkel, H; Nagel, GA; von Heyden, HW; Weinstock, N | 1 |
| Bernard, JP; Fournel, P; Jorda, M; Laennec, E; Piperno, D; Rebattu, P; Souquet, PJ; Trillet, V | 1 |
| Barbé, V; Cassuto-Viguier, E; Creisson-Ducray, A; Etienne, MC; Ferréro, JM; Fischel, JL; Formento, P; Lagrange, JL; Milano, G; Mondain, JR | 1 |
| Alimonti, A; Bedini, AV; Canevali, C; Caroli, S; Milani, F; Morazzoni, F; Moschetti, I; Petrucci, F; Ravasi, G; Todeschini, R | 1 |
| Turrisi, AT | 1 |
| Cordier, JF; Trillet-Lenoir, V | 1 |
| Hirose, N; Nagashima, A; Nakahashi, H; Shimokawa, T; Yasumoto, K | 1 |
| Canepa, M; Civalleri, D; De Cian, F; Esposito, M; Leprini, A; Ratto, GB; Romano, P; Vannozzi, MO; Zaccheo, D | 1 |
| Jones, WB; Lewis, JL; Schneider, J; Shapiro, F | 1 |
| Berthiot, G; Coninx, P; Desoize, B; Dumont, P; Manot, L | 1 |
| Bakker, PJ; Blommaert, FA; Geerdink, A; Haveman, J; Rietbroek, RC; van de Vaart, PJ; Veenhof, CH | 1 |
| Kimbara, K; Kunitoh, H; Nagatomo, A; Okamoto, H; Watanabe, K | 1 |
| Hoshi, S; Mao, H; Nose, M; Orikasa, S; Suzuki, K; Takahashi, T | 1 |
| Asoh, H; Fukuyama, Y; Ichinose, Y; Kuninaka, S; Miyagi, J; Terazaki, Y; Yano, T; Yokoyama, H | 1 |
| De Ruysscher, D; Demedts, M; Spaas, P; Specenier, P; Van den Brande, P; Vansteenkiste, J | 1 |
| Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; van der Vijgh, WJ; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
| Coosemans, W; De Leyn, P; Deneffe, G; Lerut, T; Van Raemdonck, D; Vansteenkiste, J | 1 |
| Koshino, T; Machida, J; Saito, T; Takagi, T; Watanabe, T | 1 |
| Bauer, J; Fokkema, E; Groen, HJ; Smith, IE; Uges, DR; Weil, C | 1 |
| Borges, AC; Fietze, I; Geisler, A; John, M; Romaniuk, P; Schmidt, B; Witt, Ch | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Baumgartner, G; Merrin, C; Murphy, GP; Takita, H; Wajsman, Z; Weber, R | 1 |
| Carr, DT; Coles, DT; Eagan, RT; Frytak, S; Ingle, JN; Kvols, LK; O'Fallon, JR; Rubin, J | 1 |
| Iakovlev, KI; Ivanov, VF; Konovalova, AL; Presnov, MA; Stetsenko, AI | 1 |
| Bernareggi, A; Castoldi, D; Cimino, G; Colombi, L; Fracasso, ME; Leone, R; Monzani, V; Soresi, E; Tedeschi, M; Usari, T | 1 |
| Bakri, YN; Ezzat, A; Pedersen, P | 1 |
| Elliott, WL; Farrell, NP; Hoeschele, JD; Kraker, AJ; Sercel, AD; Showalter, HD | 1 |
| Akita, H; Fijita, H; Haneda, H; Katabami, M; Kawakami, Y; Kuzumaki, N; Miyamoto, H | 1 |
| Zhang, M | 1 |
| Egorin, MJ; Haraf, DJ; Mick, R; Moormeier, JA; Ratain, MJ; Vokes, EE; Weichselbaum, RR | 1 |
| Brann, TW; Frei, E; Herman, TS; Holden, SA; Khandekar, V; Korbut, TT; Rosbe, KW; Sotomayor, EA; Teicher, BA | 1 |
| Eguchi, K; Ohe, Y; Ohmori, T; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Arimoto, T; Fujii, T; Fujita, Y; Gotoh, T; Hiramori, N; Iwasaki, Y; Kida, T; Nakagawa, M; Nakamura, T; Sakai, M | 1 |
| de Vries, EG; Hospers, GA; Mulder, NH | 1 |
| de Leij, L; de Vries, EG; Hospers, GA; Meijer, C; Mulder, NH; Uges, DR | 1 |
| Bres, J; Cupissol, D; Gestin-Boyer, C; Michel, FB; Pujol, JL; Serrou, B | 1 |
| Bacchi, M; Bassi, P; Belsanti, V; Bisagni, G; Boni, C; Cocconi, G; Lottici, R; Passalacqua, R; Tonato, M | 1 |
| Barter, JF; Hatch, KD; Orr, JW; Shingleton, HM; Soong, SJ | 1 |
| Iwamoto, Y; Sugioka, Y | 1 |
| Hoshi, A; Maeda, M; Sasaki, T; Suga, T; Takasuka, N | 1 |
| Berland, Y; Boutin, C; Bues-Charbit, M; Cano, JP; Merzouk, T; Olmer, M | 1 |
| Ikeda, T; Ishikura, T; Itaoka, T; Nakajima, H; Nitta, S; Yokoyama, M | 1 |
| Hayashibara, K; Hirosawa, A; Niitani, H; Tsuboi, E | 1 |
| de Vries, EG; Hospers, GA; Martini, IA; Meijer, C; Mulder, NH; Muskiet, FA; Timmer-Bosscha, H; Uges, DR | 1 |
| Murakami, M | 1 |
| Roed, H; Vindeløv, LL | 1 |
| DeGregorio, MW; Deisseroth, AB; Gandara, DR; George, CB; Kohler, M; Lawrence, HJ; Wilbur, BJ; Wold, H | 1 |
| Abad-Esteve, A; Fernandez, C; Monras, P; Moreno, I; Morera, J; Ribas-Mundo, M; Rosell, R; Ruiz, J | 1 |
| Boxall, FE; Calvert, AH; Gore, ME; Gumbrell, LA; Newell, DR; Siddik, ZH; Smith, IE | 1 |
| Gill, PG; Reece, PA; Russell, J; Stafford, I | 1 |
| Carter, SK | 1 |
| Carter, SK; Slavik, M | 1 |
| Dohnalová, J; Dostálová, O; Drobník, J; Fiserová, J; Holík, F | 1 |
65 review(s) available for platinum and Lung Neoplasms
| Article | Year |
|---|---|
Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Coordination Complexes; Etoposide; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2021 |
Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%-49%: A network meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Lung Neoplasms; Nivolumab; Platinum; Progression-Free Survival; Randomized Controlled Trials as Topic | 2022 |
Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2022 |
Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis.
Topics: Carcinoma, Transitional Cell; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Male; Platinum; Programmed Cell Death 1 Receptor; Urinary Bladder Neoplasms | 2022 |
BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage II-IV non-small cell lung cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Platinum; Prognosis | 2022 |
Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Network Meta-Analysis; Platinum; Vinorelbine | 2022 |
Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung; Lung Neoplasms; Platinum | 2022 |
Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Fluorouracil; Humans; Leukopenia; Lung Neoplasms; Platinum; Taxoids; Thrombocytopenia | 2022 |
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immunotherapy; Lung Neoplasms; Network Meta-Analysis; Pemetrexed; Platinum | 2023 |
Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Sunitinib; Thymoma; Thymus Neoplasms | 2023 |
Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cervix Uteri; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Staging; Platinum; Rare Diseases; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms | 2023 |
Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan | 2023 |
First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Carboplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Network Meta-Analysis; Platinum; Programmed Cell Death 1 Receptor; Small Cell Lung Carcinoma | 2023 |
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study).
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors | 2023 |
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoadjuvant Therapy; Platinum; Randomized Controlled Trials as Topic | 2023 |
Efficacy and safety of Kanglaite injection combined with first-line platinum-based chemotherapy in patients with advanced NSCLC: a systematic review and meta-analysis of 32 RCTs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drugs, Chinese Herbal; Humans; Lung Neoplasms; Platinum | 2020 |
Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic | 2021 |
Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Topics: Adult; Animals; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Lung Neoplasms; Mice; Nasopharyngeal Neoplasms; Phosphatidylinositol 3-Kinases; Platinum; Programmed Cell Death 1 Receptor; Tumor Microenvironment | 2021 |
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2021 |
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; United States; United States Food and Drug Administration | 2021 |
The impacts of race and regimens on the efficacy and safety of paclitaxel and platinum combination treatment for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lung Neoplasms; Monte Carlo Method; Neoplasm Staging; Paclitaxel; Platinum; Survival Analysis | 2021 |
Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and meta-analysis of
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; China; Dexamethasone; Humans; Lung Neoplasms; Morpholines; Nausea; Platinum; Randomized Controlled Trials as Topic; Receptors, Serotonin, 5-HT3; Vomiting | 2021 |
Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Repair; Humans; Lung Neoplasms; Neoplasm Proteins; Platinum; Polymorphism, Genetic | 2017 |
Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.
Topics: Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; Humans; Lung Neoplasms; Molecular Epidemiology; Pharmacogenetics; Platinum; Polymorphism, Single Nucleotide; Treatment Outcome | 2017 |
The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Platinum | 2017 |
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Risk Assessment; Risk Factors | 2018 |
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Progression-Free Survival; Treatment Outcome | 2018 |
STAT3 rs4796793 contributes to lung cancer risk and clinical outcomes of platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Case-Control Studies; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide; Prognosis; STAT3 Transcription Factor; Treatment Outcome | 2019 |
Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Quinazolines; Smoking | 2013 |
Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA-Binding Proteins; Endonucleases; Humans; Lung Neoplasms; Neoplasm Staging; Odds Ratio; Platinum; Polymorphism, Single Nucleotide; Publication Bias; Risk; Treatment Outcome | 2013 |
Systemic therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lung Neoplasms; Platinum; Recurrence; Small Cell Lung Carcinoma | 2013 |
Current concepts in the management of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Platinum; Randomized Controlled Trials as Topic; Recurrence; Small Cell Lung Carcinoma; Treatment Outcome | 2013 |
Platinum rechallenge in patients with advanced NSCLC: a pooled analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Staging; Odds Ratio; Platinum; Publication Bias; Retreatment; Treatment Outcome | 2013 |
XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis.
Topics: Alleles; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Humans; Lung Neoplasms; Platinum; Polymorphism, Genetic; Treatment Outcome | 2013 |
Predictive effect of XRCC3 Thr241Met polymorphism on platinum-based chemotherapy in lung cancer patients: meta-analysis.
Topics: Amino Acid Substitution; DNA-Binding Proteins; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Platinum; Polymorphism, Genetic; Prognosis; Survival Analysis; Treatment Outcome | 2013 |
XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome | 2013 |
Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Methylenetetrahydrofolate Reductase (NADPH2); Platinum; Polymorphism, Genetic | 2013 |
The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Humans; Lung Neoplasms; Platinum; Polymorphism, Single Nucleotide; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2014 |
[A meta-analysis of platinum plus docetaxel or vinorelbine in the first-line treatment of advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2014 |
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Survival Rate | 2015 |
Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Platinum | 2016 |
Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; DNA-Binding Proteins; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Odds Ratio; Pharmacogenetics; Platinum; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2015 |
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma | 2016 |
Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; DNA Repair; DNA-Binding Proteins; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Platinum; Polymorphism, Single Nucleotide; X-ray Repair Cross Complementing Protein 1 | 2016 |
Can Aidi injection restore cellular immunity and improve clinical efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy? A meta-analysis of 17 randomized controlled trials following the PRISMA guidelines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drugs, Chinese Herbal; Humans; Immunity, Cellular; Injections; Lung Neoplasms; Phytotherapy; Platinum; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2017 |
Research Advances in Resistance to Platinum-based Chemotherapy in Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Platinum; Prognosis | 2017 |
A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Databases, Bibliographic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Platinum; Vinblastine; Vinorelbine | 2009 |
[A meta analysis of gemcitabine plus platinum chemotherapy compared with single-agent chemotherapy in the treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Platinum; Treatment Outcome | 2010 |
[A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Platinum; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2011 |
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
Problems involved in the clinical trials for non-small cell lung carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Patient Selection; Pemetrexed; Platinum; Quinazolines | 2012 |
Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Meta-Analysis as Topic; Platinum; Standard of Care | 2012 |
Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Genetic Heterogeneity; Genetic Variation; Humans; Lung Neoplasms; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Publication Bias; Treatment Outcome | 2012 |
Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Endostatins; Humans; Leukopenia; Lung Neoplasms; Nausea; Platinum; Randomized Controlled Trials as Topic; Recombinant Proteins; Thrombocytopenia; Treatment Outcome; Vomiting | 2011 |
Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.
Topics: Alleles; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Neoplasm Staging; Platinum; Polymorphism, Genetic; Prognosis; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2012 |
Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pharmacogenetics; Platinum; Polymorphism, Single Nucleotide; Prognosis | 2012 |
Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Survival Analysis; Treatment Outcome | 2013 |
A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Humans; Lung Neoplasms; Platinum; Polymorphism, Genetic | 2012 |
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; DNA-Binding Proteins; Endonucleases; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Platinum; Prognosis; Risk Factors; RNA, Neoplasm | 2007 |
Optimal duration of chemotherapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Administration Schedule; ErbB Receptors; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Platinum; Quality of Life; Time Factors; Treatment Outcome | 2007 |
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2008 |
The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; DNA Repair; DNA-Binding Proteins; Endonucleases; Humans; Lung Neoplasms; Platinum; Predictive Value of Tests; Survival Rate | 2008 |
[Origin of small cell lung cancers].
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Neoplasm Metastasis; Platinum; Podophyllotoxin | 1993 |
Can human small-cell lung cancer cell lines be applied for optimizing chemotherapy?
Topics: Animals; Carcinoma, Small Cell; Colony-Forming Units Assay; DNA, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Nitrosourea Compounds; Platinum; Podophyllotoxin; Tumor Cells, Cultured | 1989 |
129 trial(s) available for platinum and Lung Neoplasms
| Article | Year |
|---|---|
Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immuno
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Pemetrexed; Platinum; Radiosurgery; Tumor Microenvironment | 2022 |
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Indoles; Lung Neoplasms; Platinum; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2021 |
Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed-Platinum-Radiation in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: Results of a Phase I Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Repair; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2022 |
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Double-Blind Method; Etoposide; Follow-Up Studies; Humans; Immunotherapy; Lung Neoplasms; Markov Chains; Medicare; Neoplasm Staging; Platinum; Progression-Free Survival; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; United States | 2021 |
CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Platinum | 2022 |
A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alter
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Ipilimumab; Lung Neoplasms; Nivolumab; Platinum; Programmed Cell Death 1 Receptor | 2022 |
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2022 |
A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Etoposide; Humans; Indoles; Lung Neoplasms; Platinum; Prospective Studies; Quinolines; Small Cell Lung Carcinoma | 2022 |
Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Paclitaxel; Platinum | 2022 |
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Programmed Cell Death 1 Receptor; Ramucirumab | 2022 |
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Pemetrexed; Platinum; Receptor Protein-Tyrosine Kinases | 2022 |
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Platinum | 2022 |
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Humans; Lung Neoplasms; Platinum; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2022 |
Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2023 |
A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiatio
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Consolidation Chemotherapy; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Platinum; Prospective Studies; Protein Kinase Inhibitors | 2022 |
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Pain; Patient Reported Outcome Measures; Platinum; Quality of Life | 2023 |
Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Platinum | 2023 |
Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Killer Cells, Natural; Lung Neoplasms; Pilot Projects; Platinum | 2022 |
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemothera
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors | 2023 |
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Pemetrexed; Platinum; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2023 |
Patients' voice and passion lead to successful clinical trial, KISEKI study; Comments on "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progresse
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors | 2023 |
FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Platinum | 2023 |
Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Irinotecan; Lung Neoplasms; Platinum | 2023 |
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Pain; Patient Reported Outcome Measures; Platinum; Quality of Life | 2023 |
Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Thyroid Nuclear Factor 1 | 2023 |
Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; CTLA-4 Antigen; Humans; Lung Neoplasms; Platinum | 2023 |
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Platinum; Quality of Life | 2023 |
Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
Topics: Disease Progression; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2023 |
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.
Topics: Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Platinum; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Survival Analysis | 2023 |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors | 2023 |
Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Nivolumab; Platinum; Prospective Studies; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Topotecan | 2023 |
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoadjuvant Therapy; Nivolumab; Platinum; Prospective Studies | 2023 |
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Predictive Value of Tests; Protein Kinase Inhibitors; Proteomics; Survival Rate | 2019 |
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Tre
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Double-Blind Method; Etoposide; Humans; Lung Neoplasms; Picornaviridae; Platinum | 2020 |
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Albumins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasm Staging; Platinum; Ramucirumab | 2020 |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Platinum; Taiwan | 2020 |
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Platinum | 2020 |
Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oligopeptides; Platinum; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2020 |
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Small Cell Lung Carcinoma; Survival Analysis | 2020 |
Pyrotinib in
Topics: Acrylamides; Adenocarcinoma; Adolescent; Adult; Aged; Aminoquinolines; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Young Adult | 2020 |
A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Topics: Acrylamides; Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Survival Analysis | 2020 |
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Patient Reported Outcome Measures; Platinum; Quality of Life | 2020 |
Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nivolumab; Platinum; Progression-Free Survival; Prospective Studies; Small Cell Lung Carcinoma; Thorax | 2021 |
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Progression-Free Survival; Safety; Treatment Outcome | 2021 |
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; ROC Curve | 2021 |
Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Platinum; Prospective Studies; Quality of Life; Vinorelbine | 2021 |
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
Topics: Antibodies, Monoclonal, Humanized; Asia; Docetaxel; Europe; Humans; Immune Checkpoint Inhibitors; Lung; Lung Neoplasms; Platinum | 2021 |
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2021 |
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Double-Blind Method; Humans; Immunoconjugates; Lung Neoplasms; Middle Aged; Platinum | 2021 |
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Docetaxel; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum | 2021 |
The efficacy of music therapy to relieve pain, anxiety, and promote sleep quality, in patients with small cell lung cancer receiving platinum-based chemotherapy.
Topics: Anxiety; Humans; Lung Neoplasms; Music Therapy; Pain; Platinum; Sleep; Small Cell Lung Carcinoma | 2021 |
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Lung Neoplasms; Platinum | 2021 |
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Humans; Lung Neoplasms; Platinum; Survival Analysis | 2021 |
[Detection of Serum Peptides in Patients with Lung Squamous Cell Carcinoma by MALDI-TOF-MS and Analysis of Their Correlation with Chemotherapy Efficacy].
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peptides; Platinum; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Young Adult | 2017 |
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Platinum; Protein Kinase Inhibitors; Remission Induction; Risk Assessment; United States; United States Food and Drug Administration; Young Adult | 2018 |
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Middle Aged; Mutation; Piperazines; Platinum; Propensity Score; Protein Kinase Inhibitors | 2018 |
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Platinum; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Anemia; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Piperazines; Platinum; Protein Kinase Inhibitors; Young Adult | 2018 |
Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy.
Topics: Aged; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Platinum | 2018 |
Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Female; Humans; Janus Kinases; Lung Neoplasms; Male; MAP Kinase Kinase 1; Middle Aged; Mutation; Neoplasm Metastasis; Platinum; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidines; Pyrimidinones; Treatment Failure | 2018 |
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Pemetrexed; Platinum; Progression-Free Survival; Prospective Studies; Retrospective Studies | 2018 |
Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pemetrexed; Platinum; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2019 |
AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany.
Topics: Aged; Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Female; Germany; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Platinum; Standard of Care; Survival Analysis; Treatment Outcome | 2019 |
A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Treatment Outcome | 2019 |
The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Female; Gene Frequency; Genetic Association Studies; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Treatment Outcome | 2013 |
A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
Topics: Adult; Aged; Carboplatin; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Proportional Hazards Models; Radiotherapy Dosage; Small Cell Lung Carcinoma | 2013 |
Phase II study on Javanica oil emulsion injection (Yadanzi®) combined with chemotherapy in treating patients with advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brucea; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Emulsions; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Phytotherapy; Plant Oils; Platinum; Prognosis | 2013 |
Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Proliferation; Chemoradiotherapy; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Neutrophils; Organ Specificity; Platinum; Positron-Emission Tomography; Spleen; Tomography, X-Ray Computed | 2014 |
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Serine; Taxoids; Treatment Outcome | 2014 |
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Platinum; Quality of Life; Ramucirumab; Survival Rate; Taxoids | 2014 |
Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA-Directed DNA Polymerase; Female; Genotyping Techniques; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide; Treatment Outcome | 2014 |
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking | 2014 |
[Comparison of the effectiveness of platinum-based chemotherapy versus non-platinum-based chemotherapy for triple-negative breast cancer with metastases confined to the lungs].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lung Neoplasms; Neoplasms, Second Primary; Platinum; Triple Negative Breast Neoplasms | 2014 |
Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2015 |
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Platinum; Retreatment; Taxoids; Tegafur; Treatment Outcome | 2015 |
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Genotype; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Prognosis; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2015 |
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Platinum; Proportional Hazards Models; Quality of Life; Ramucirumab; Retreatment; Taxoids; Treatment Outcome | 2016 |
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Treatment Outcome | 2016 |
DNA repair gene polymorphisms in non-small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Repair; Female; Gene Frequency; Genes, erbB-1; Genes, ras; Genetic Predisposition to Disease; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Risk Factors | 2016 |
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Ramucirumab; Retreatment; Risk Factors; Taxoids; Treatment Outcome | 2016 |
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Quinazolines | 2017 |
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Piperazines; Platinum; Young Adult | 2017 |
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic On
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Prognosis; Survival Rate; Taxoids | 2017 |
Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dietary Supplements; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Pemetrexed; Platinum; Pleural Neoplasms; Vitamins | 2009 |
Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Staging; Nuclear Proteins; Platinum; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2010 |
Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; Female; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Treatment Outcome | 2010 |
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2011 |
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Platinum; Salvage Therapy; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2011 |
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prospective Studies; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2010 |
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Early Termination of Clinical Trials; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Patient Dropouts; Platinum; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2011 |
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2011 |
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Guidelines as Topic; Health Care Costs; Humans; Lung Neoplasms; Models, Economic; Platinum; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom | 2011 |
[Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2011 |
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Dioxoles; DNA-Binding Proteins; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Platinum; Tetrahydroisoquinolines; Trabectedin; Transcription Factors; Treatment Outcome | 2012 |
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Ethers, Cyclic; Female; Follow-Up Studies; Furans; Humans; Ketones; Lung Neoplasms; Macrolides; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Platinum; Pyrroles; Salvage Therapy; Stomach Neoplasms; Sunitinib; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Failure; United States | 2012 |
Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Survival Analysis; Treatment Outcome | 2013 |
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Prognosis; Proportional Hazards Models; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cyclobutanes; Dicarboxylic Acids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Platinum; Thrombocytopenia; Vomiting | 2013 |
Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; DNA-Binding Proteins; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Platinum; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Transcription Factors; Transcription Initiation Site; Treatment Outcome; Young Adult | 2013 |
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Platinum; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Treatment Outcome | 2013 |
[Prospective study on surface-enhanced laser desorption/ionization protein fingerprinting for diagnosing gene polymorphism leading to drug resistance drift: sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Prospective Studies; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2013 |
Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Darbepoetin alfa; Double-Blind Method; Drug Administration Schedule; Erythrocyte Transfusion; Erythropoietin; Female; Hemoglobins; Humans; Lung Neoplasms; Lymphoproliferative Disorders; Male; Middle Aged; Platinum; Population Surveillance; Sex Factors; Treatment Outcome | 2002 |
Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum.
Topics: Adult; Aftercare; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Survival Rate; Vinblastine; Vinorelbine | 2004 |
Peripheral lung nodules: fluoroscopically guided video-assisted thoracoscopic resection after computed tomography-guided localization using platinum microcoils.
Topics: Female; Fluoroscopy; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Platinum; Preoperative Care; Radiography, Interventional; Solitary Pulmonary Nodule; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2004 |
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Platinum; Thrombocytopenia; Topotecan; Treatment Outcome | 2005 |
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Patient Compliance; Platinum; Prospective Studies; Psychomotor Performance; Quality of Life; Sickness Impact Profile; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Platinum; Survival Rate | 2006 |
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer.
Topics: Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Adducts; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Leukocytes; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Platinum; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Confidence Intervals; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Platinum; Probability; Pyrazoles; Quinazolines; Risk Assessment; Sulfonamides; Survival Analysis | 2007 |
[Results of a combination of platinum-vindesin-ametycin-bleomycin (CEMB) in the treatment of stage IV non-small-cell lung cancers].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Platinum; Vindesine | 1993 |
Determination of platinum in plasma of patients affected by inoperable lung carcinoma treated with radiotherapy and concurrent low-dose continuous infusion of cis-dichlorodiammine platinum(II).
Topics: Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Computer Simulation; Humans; Infusions, Intravenous; Lung Neoplasms; Mass Spectrometry; Platinum | 1995 |
Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Platinum; Prospective Studies | 1996 |
Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Platinum; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Vindesine | 1998 |
Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Ifosfamide; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinoscopy; Middle Aged; Neoplasm Staging; Platinum; Pneumonectomy; Prognosis; Prospective Studies; Remission Induction; Survival Analysis; Survival Rate; Vindesine | 1999 |
Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Platinum; Treatment Outcome | 1999 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Galactitol; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Sugar Alcohols | 1977 |
Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Interactions; Drug Therapy, Combination; Etoposide; Glutathione; Half-Life; Humans; Lung Neoplasms; Mesothelioma; Platinum; Pleural Neoplasms; Time Factors | 1992 |
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Leucovorin; Lung Neoplasms; Male; Middle Aged; Platinum | 1992 |
Effects of sodium thiosulfate in combination therapy of cis-dichlorodiammineplatinum and vindesine.
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Humans; Kidney; Lung Neoplasms; Platinum; Random Allocation; Thiosulfates; Time Factors; Vindesine | 1989 |
A randomized study comparing platinum, doxorubicin, and VP-16 with platinum, 4'-epidoxorubicin, and VP-16 in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Podophyllotoxin; Random Allocation | 1987 |
425 other study(ies) available for platinum and Lung Neoplasms
| Article | Year |
|---|---|
Glutathione peroxidase 4-dependent glutathione high-consumption drives acquired platinum chemoresistance in lung cancer-derived brain metastasis.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Ferroptosis; Glutathione; Glutathione Transferase; Humans; Lung Neoplasms; Mice; Phospholipid Hydroperoxide Glutathione Peroxidase; Platinum | 2021 |
A simple dilute-and-shoot procedure for the determination of platinum in human pleural effusions using HR-CS GF-AAS.
Topics: Cytostatic Agents; Graphite; Humans; Lung Neoplasms; Platinum; Pleural Effusion | 2021 |
Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prospective Studies; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2022 |
Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum | 2022 |
Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Platinum; Small Cell Lung Carcinoma | 2021 |
Heterogeneous radiological response to chemotherapy is associated with poor prognosis in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival | 2021 |
Intestinal flora characteristics of advanced non-small cell lung cancer in China and their role in chemotherapy based on metagenomics: A prospective exploratory cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cohort Studies; Female; Gastrointestinal Microbiome; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Metagenomics; Middle Aged; Platinum; Prospective Studies | 2021 |
Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Platinum; Predictive Value of Tests; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2021 |
Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Humans; Lung Neoplasms; Platinum; Prognosis; Retrospective Studies | 2021 |
Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Retrospective Studies; Treatment Outcome | 2021 |
Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Progression-Free Survival; Retrospective Studies | 2021 |
Effects of Shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Combinations; Drugs, Chinese Herbal; Humans; Immunity; Lung Neoplasms; Meta-Analysis as Topic; Platinum; Prognosis; Quality of Life; Research Design; Systematic Reviews as Topic | 2021 |
Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Immunotherapy; Lung Neoplasms; Mutation; Platinum; Retrospective Studies | 2022 |
Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Geriatric Assessment; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Nutrition Assessment; Platinum; Retrospective Studies; Risk Factors; Survival Rate | 2021 |
Association of
Topics: Antineoplastic Agents; Arylamine N-Acetyltransferase; Female; Genetic Predisposition to Disease; Humans; India; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide; Prognosis; Smoking; Survival Analysis | 2022 |
Transcriptomics reveals
Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cholesterol; Cisplatin; Humans; Integrins; Lung Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Ribose; Transcriptome; Transforming Growth Factor beta | 2022 |
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Treatment Outcome | 2022 |
[Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neutropenia; Pemetrexed; Platinum; Pleural Neoplasms | 2022 |
Hypoxia-Responsive Platinum Supernanoparticles for Urinary Microfluidic Monitoring of Tumors.
Topics: Animals; Hypoxia; Lung Neoplasms; Mice; Microfluidics; Platinum; Point-of-Care Systems | 2022 |
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Platinum; Retrospective Studies | 2022 |
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Platinum; United States | 2022 |
Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: A multicentre retrospective study.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Induction Chemotherapy; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Retrospective Studies | 2022 |
Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum; Prospective Studies; Retrospective Studies | 2023 |
Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; CTLA-4 Antigen; Humans; Lung Neoplasms; Platinum | 2022 |
VEGF single nucleotide polymorphisms predict improved outcome in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Genotype; Humans; Lung Neoplasms; Platinum; Polymorphism, Single Nucleotide; Vascular Endothelial Growth Factor A | 2023 |
Comparative survival analysis of platinum-based adjuvant chemotherapy for early-stage squamous cell carcinoma and adenocarcinoma of the lung.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Humans; Lung; Lung Neoplasms; Neoplasm Staging; Platinum; Survival Analysis | 2022 |
Platinum-Based Chemotherapy 'Rechallenge' in Advanced Non-ovarian Solid Malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Platinum; Quality of Life | 2022 |
Design of a novel Pt(II) complex to reverse cisplatin-induced resistance in lung cancer
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Platinum | 2022 |
Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2022 |
Association of variations in the Fanconi anemia complementation group and prognosis in Non-small cell lung cancer patients with Platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Fanconi Anemia; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide | 2022 |
Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
The endocytosis of nano-Pt into non-small cell lung cancer H1299 cells and intravital therapeutic effect in vivo.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endocytosis; Humans; Lung Neoplasms; Mice; Platinum | 2022 |
Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Retrospective Studies | 2022 |
The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Humans; Immune Checkpoint Inhibitors; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Mutation; NF-E2-Related Factor 2; Pemetrexed; Platinum; Prevalence; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Taxoids | 2022 |
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
Topics: Biomarkers; Biomarkers, Tumor; Cell Line, Tumor; DNA; Humans; Lung Neoplasms; Neoplastic Cells, Circulating; Nuclear Proteins; Platinum; Small Cell Lung Carcinoma | 2022 |
Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non-small cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2023 |
BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Humans; Immunohistochemistry; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Pleural Neoplasms; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2022 |
Mechanism of vitamin B6 benzoyl hydrazone platinum(II) complexes overcomes multidrug resistance in lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Copper; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Hydrazones; Lung Neoplasms; Platinum; Vitamin B 6 | 2022 |
Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
Topics: Brain Neoplasms; Etoposide; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Platinum; Quinolines; Small Cell Lung Carcinoma | 2022 |
How platinum-induced nephrotoxicity occurs? Machine learning prediction in non-small cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Neoplasms; Machine Learning; Platinum | 2022 |
Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor-β as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer.
Topics: Activins; Adult; Biomarkers; Bone Morphogenetic Proteins; Carcinoma, Non-Small-Cell Lung; Growth Differentiation Factors; Humans; Lung Neoplasms; Organoplatinum Compounds; Platinum; Prospective Studies; Retrospective Studies; Transforming Growth Factor beta; Transforming Growth Factors | 2022 |
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutagenesis, Insertional; Mutation; Platinum; Protein Kinase Inhibitors | 2022 |
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2022 |
Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies | 2022 |
THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients.
Topics: Cisplatin; Humans; Lung Neoplasms; Mutation; Platinum; Small Cell Lung Carcinoma | 2022 |
Real-world treatment pattern and comprehensive comparative effectiveness of Endostar plus different chemotherapy in advanced patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Endostatins; Humans; Lung Neoplasms; Pemetrexed; Platinum; Recombinant Proteins | 2022 |
Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
Computed Tomography Image under Artificial Intelligence Algorithm to Evaluate the Nursing and Treatment Effect of Pemetrexed Combined Platinum-Based Chemotherapy on Elderly Lung Cancer.
Topics: Aged; Antigens, Neoplasm; Artificial Intelligence; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Keratin-19; Lung Neoplasms; Pemetrexed; Platinum; Tomography; Tomography, X-Ray Computed | 2022 |
Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Prospective Studies; Protein Kinase Inhibitors; Treatment Failure | 2022 |
Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Quinolines; Small Cell Lung Carcinoma | 2022 |
Does Molecular Profiling of
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Proto-Oncogene Proteins p21(ras) | 2022 |
Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Topics: Animals; Cell Death; Enzyme Inhibitors; Etoposide; Histone Demethylases; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lysine; Mice; Platinum; Small Cell Lung Carcinoma; Tumor Microenvironment | 2022 |
Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Retrospective Studies; Thymoma; Thymus Neoplasms | 2023 |
Study on the Predictive Value of P53 Protein Expression in Brain Metastasis in NSCLC and the Mechanism of miR-424 Reversing Platinum Resistance in NSCLC.
Topics: Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; MicroRNAs; Platinum; Retrospective Studies; Tumor Suppressor Protein p53 | 2022 |
Mutational landscape of homologous recombination-related genes in small-cell lung cancer.
Topics: B7-H1 Antigen; Biomarkers, Tumor; Homologous Recombination; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2022 |
Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Prospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2022 |
Precise quantitative evaluation of pharmacokinetics of cisplatin using a radio-platinum tracer in tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Cisplatin; Humans; Lung Neoplasms; Mice; Mice, Nude; Platinum; Tissue Distribution | 2022 |
What's Current and What's New in Mesothelioma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Pleural Neoplasms | 2022 |
A miR-15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum-based chemotherapy.
Topics: 3' Untranslated Regions; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Humans; Lung Neoplasms; MicroRNAs; Platinum; Polymorphism, Single Nucleotide | 2022 |
Efficacy, safety, and prognostic factors of apatinib plus platinum doublet chemotherapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Platinum; Prognosis; Pyridines; Retrospective Studies; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Immunotherapy and Prognosis of Non-small Cell Lung Carcinoma by Monomethoxy polyethylene glycol-hyaluronic acid-platinum Combined with Immune CT4+ and CT8+ Detection.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Hyaluronic Acid; Immunotherapy; Lung Neoplasms; Platinum; Polyethylene Glycols | 2022 |
PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Topics: Carcinoma, Squamous Cell; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Retrospective Studies | 2022 |
Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2022 |
Prevalence, Treatment Patterns, and Outcomes of Individuals with
Topics: Afatinib; Alberta; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Platinum; Prevalence | 2022 |
A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; Humans; Lung Neoplasms; Pemetrexed; Platinum; Proto-Oncogene Proteins p21(ras) | 2022 |
[Neoadjuvant nivolumab in combination with platinum-based chemotherapy for operable lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoadjuvant Therapy; Nivolumab; Platinum | 2023 |
Zebrafish patient-derived xenografts accurately and quickly reproduce treatment outcomes in non-small cell lung cancer patients.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Heterografts; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Treatment Outcome; Zebrafish | 2023 |
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams, Macrocyclic; Lung Neoplasms; Pemetrexed; Platinum; Protein Kinase Inhibitors | 2023 |
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.
Topics: Aged; Female; Humans; Lung Neoplasms; Male; Patient Acceptance of Health Care; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Activation of the TGF-
Topics: Carcinoma, Small Cell; Humans; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma | 2022 |
Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Follow-Up Studies; Humans; Lung Neoplasms; Peripheral Nervous System Diseases; Platinum; Prospective Studies | 2023 |
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Male; Platinum; Retrospective Studies | 2023 |
The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Endonucleases; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Prospective Studies; Thymidylate Synthase; Treatment Outcome | 2023 |
Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Platinum; Prognosis | 2023 |
Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Topics: Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
[Drug approval: ATEZOLIZUMAB as monotherapy in NSCLC PD-L1 ≥ 50%, without EGFR mutation or ALK rearrangement, for adjuvant treatment after complete surgery and platinum-based chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Platinum; Receptor Protein-Tyrosine Kinases | 2023 |
A Non-Conventional Platinum Drug against a Non-Small Cell Lung Cancer Line.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Neoplasms; Platinum | 2023 |
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; NF-E2-Related Factor 2; Platinum; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Taxoids | 2023 |
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Platinum; Ramucirumab; Retrospective Studies; Taxoids | 2023 |
Disulfiram enhances cisplatin cytotoxicity by forming a novel platinum chelate Pt(DDTC)
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disulfiram; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mice; Platinum | 2023 |
Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Platinum; Retrospective Studies; Vinblastine; Vinorelbine | 2023 |
Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Propensity Score; Small Cell Lung Carcinoma | 2023 |
Cellular immunotherapy combined with platinum-based chemotherapy prolongs survival for non-small cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Platinum; Retrospective Studies | 2023 |
First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Novel 4-Amino-Quinazoline moieties ligated Platinum(IV) prodrugs overcome cisplatin resistance in EGFR
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Oxaliplatin; Phosphatidylinositol 3-Kinases; Platinum; Prodrugs | 2023 |
Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Hospitals; Humans; Japan; Lung Neoplasms; Platinum; Prospective Studies | 2023 |
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutagenesis, Insertional; Mutation; Platinum; Protein Kinase Inhibitors; Standard of Care | 2023 |
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Topics: Animals; Etoposide; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-myc; Small Cell Lung Carcinoma | 2023 |
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Ipilimumab; Lung Neoplasms; Neoadjuvant Therapy; Nivolumab; Platinum; United States; United States Food and Drug Administration | 2023 |
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Early Detection of Cancer; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma | 2023 |
Association of
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Genotype; Humans; Lung Neoplasms; MutL Protein Homolog 1; Platinum; Polymorphism, Single Nucleotide | 2023 |
Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer: The Piedmont Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Folic Acid Antagonists; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies | 2023 |
Nano-Pt induced mitochondria-dependent apoptosis and cytoprotective autophagy in human NSCLC cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Mitochondria; Platinum | 2023 |
FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Recurrence, Local; Platinum; Protein Kinase Inhibitors; Retrospective Studies | 2023 |
Platinum-combination chemotherapy with or without immune-checkpoint inhibitor in patients with postoperative recurrent non-small cell lung cancer previously treated with adjuvant platinum-doublet chemotherapy: A multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Retrospective Studies | 2023 |
The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2023 |
Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligible.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Platinum | 2023 |
Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Inpatients; Lung Neoplasms; Platinum; Retrospective Studies; Thrombosis; Venous Thromboembolism | 2023 |
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Treatment Outcome | 2023 |
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; NF-E2-Related Factor 2; Platinum; Protein Serine-Threonine Kinases | 2023 |
CRTAC1 enhances the chemosensitivity of non-small cell lung cancer to cisplatin by eliciting RyR-mediated calcium release and inhibiting Akt1 expression.
Topics: Animals; Calcium; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Mice; Platinum | 2023 |
Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies | 2023 |
[Small cell lung cancer heterogeneity and molecular subtypes: biological and clinical relevance].
Topics: Clinical Relevance; Humans; Immunotherapy; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2023 |
Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors | 2023 |
In stage IV pulmonary adenocarcinoma patients, treatment with Traditional Chinese Medicine alone gives prognostically superior results to treatment with Platinum-Based Chemotherapy alone.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Drugs, Chinese Herbal; Humans; Lung Neoplasms; Medicine, Chinese Traditional; Platinum | 2023 |
Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Delivery of Health Care; Humans; Lung Neoplasms; Platinum; Reproducibility of Results | 2023 |
Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Humans; Japan; Lung Neoplasms; Platinum; Quality-Adjusted Life Years | 2023 |
DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Damage; ErbB Receptors; Humans; Immunotherapy; Lung Neoplasms; Mutation; Platinum; Receptor Protein-Tyrosine Kinases | 2023 |
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutagenesis, Insertional; Mutation; Platinum; Protein Kinase Inhibitors | 2023 |
IPSOS trial: A "game changer" redefining first-line immunotherapy in platinum-ineligible NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Immunotherapy; Lung Neoplasms; Platinum | 2023 |
Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Topics: B7-H1 Antigen; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it?
Topics: DNA Damage; Humans; Lung Neoplasms; Mutation; Platinum; Small Cell Lung Carcinoma | 2019 |
Functional outcomes and survival after surgical stabilization for inoperable non-small-cell lung cancer with spinal metastasis of the thoracic and lumbar spines: a retrospective comparison between epidermal growth factor receptor-tyrosine kinase inhibitor
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Humans; Lumbar Vertebrae; Lung Neoplasms; Male; Middle Aged; Orthopedic Procedures; Outcome Assessment, Health Care; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Spinal Neoplasms; Thoracic Vertebrae | 2020 |
Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
Topics: Adenocarcinoma of Lung; Aged; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Fanconi Anemia Complementation Group N Protein; Female; Follow-Up Studies; Germ-Line Mutation; Homologous Recombination; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2019 |
First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2019 |
Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; Disease-Free Survival; Humans; Lung Neoplasms; Models, Economic; Platinum; Pyrimidines; Quality-Adjusted Life Years; Sulfones | 2019 |
Immunotherapy: a new era in small-cell lung cancer.
Topics: Antibodies, Monoclonal; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Platinum | 2019 |
Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy.
Topics: Adenocarcinoma of Lung; Adult; Aged; Circulating Tumor DNA; Cohort Studies; Female; Gene Silencing; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Polymorphism, Single Nucleotide; Prognosis; Smoking | 2019 |
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors.
Topics: Drug Therapy, Combination; Family Characteristics; Humans; Lung Neoplasms; Pemetrexed; Platinum; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Retrospective Studies | 2020 |
Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome; United Kingdom | 2019 |
Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.
Topics: Activins; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cachexia; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mesothelioma, Malignant; Middle Aged; Platinum; Pleural Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; ROC Curve | 2020 |
DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing.
Topics: Cisplatin; DNA Damage; Exome; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Mutation; Platinum; Small Cell Lung Carcinoma | 2019 |
In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing.
Topics: Cisplatin; DNA Damage; Exome; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Mutation; Platinum; Small Cell Lung Carcinoma | 2019 |
Programmed co-delivery of platinum nanodrugs and gemcitabine by a clustered nanocarrier for precision chemotherapy for NSCLC tumors.
Topics: A549 Cells; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Lung Neoplasms; Metal Nanoparticles; Platinum | 2020 |
Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
Topics: A549 Cells; Aged; Aged, 80 and over; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Inhibitors; Extracellular Vesicles; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Platinum; Prognosis; Small Cell Lung Carcinoma; Ubiquitin Thiolesterase; Up-Regulation | 2020 |
Platinum-based combination chemotherapy triggers cancer cell death through induction of BNIP3 and ROS, but not autophagy.
Topics: A549 Cells; Adenine; Antineoplastic Agents; Autophagy; Cell Death; Drug Therapy, Combination; Humans; Lung Neoplasms; Membrane Proteins; Mitochondria; Mitochondrial Membranes; Models, Biological; Platinum; Protein Transport; Proto-Oncogene Proteins; Reactive Oxygen Species | 2020 |
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Follow-Up Studies; Genomics; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Mutation; Platinum; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Rate | 2020 |
[Meta-analysis of Cinobufacini Injection combined with platinum-contained first-line chemotherapy in treatment of non-small cell lung cancer].
Topics: Amphibian Venoms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Male; Platinum; Quality of Life | 2019 |
Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced
Topics: Acrylamides; Aniline Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Treatment Outcome | 2020 |
A BODIPY-based fluorescent sensor for the detection of Pt2+ and Pt drugs.
Topics: A549 Cells; Boron Compounds; Cisplatin; Fluorescent Dyes; Humans; Ligands; Lung Neoplasms; Molecular Structure; Optical Imaging; Platinum; Spectrometry, Fluorescence | 2020 |
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Acceptance of Health Care; Platinum; Ramucirumab; Taxoids | 2021 |
The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase 6; Humans; Lung Neoplasms; Mice, SCID; Mutation; Ovarian Neoplasms; Platinum; Protein Binding; Protein Stability; Signal Transduction; Substrate Specificity; Tumor Suppressor Protein p53; Ubiquitin Thiolesterase; Ubiquitination; Xenograft Model Antitumor Assays | 2020 |
The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Lymphocytes; Neutrophils; Nutrition Assessment; Platinum; Prognosis; Retrospective Studies | 2020 |
Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases.
Topics: Biomarkers, Tumor; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Muscle Tissue; Pemetrexed; Platinum | 2020 |
Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinolines; Retrospective Studies | 2020 |
Fibrosis or Necrosis in Resected Lymph Node Indicate Metastasis Before Chemoradiotherapy in Lung Cancer Patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fibrosis; Humans; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Necrosis; Neoplasm Staging; Platinum; Tomography, X-Ray Computed | 2020 |
Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2022 |
The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy.
Topics: Ankyrins; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Neoplasm Staging; Platinum; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Small Cell Lung Carcinoma; Tyrosine | 2020 |
[Efficacy of Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinomas Refractory to Platinum-Based Chemotherapy].
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Treatment Outcome | 2020 |
Discovery of a Chiral DNA-Targeted Platinum-Acridine Agent with Potent Enantioselective Anticancer Activity.
Topics: Acridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coordination Complexes; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Molecular Structure; Platinum; Stereoisomerism; Structure-Activity Relationship | 2020 |
Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Humans; Lung Neoplasms; Male; Nivolumab; Platinum | 2020 |
Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh.
Topics: Bangladesh; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Female; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Platinum; Polymorphism, Single Nucleotide; Predictive Value of Tests; X-ray Repair Cross Complementing Protein 1 | 2020 |
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Humans; Immune Checkpoint Inhibitors; Immunosenescence; Immunotherapy; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor | 2021 |
Evaluation of a Platinum-Acridine Anticancer Agent and Its Liposomal Formulation in an in vivo Model of Lung Adenocarcinoma.
Topics: A549 Cells; Acridines; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Proliferation; Drug Compounding; Drug Screening Assays, Antitumor; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Models, Biological; Molecular Structure; Neoplasms, Experimental; Organoplatinum Compounds; Platinum | 2021 |
Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer.
Topics: Antibodies, Monoclonal, Humanized; Double-Blind Method; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Platinum nanozyme-encapsulated poly(amidoamine) dendrimer for voltammetric immunoassay of pro-gastrin-releasing peptide.
Topics: Biosensing Techniques; Dendrimers; Electrochemical Techniques; Gastrin-Releasing Peptide; Gold; Humans; Immunoassay; Limit of Detection; Lung Neoplasms; Metal Nanoparticles; Platinum; Polyamines | 2020 |
Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: Design of the multicenter PGxLUNG study.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Pharmacogenomic Variants; Platinum; Prospective Studies | 2020 |
The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
Topics: Aged; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Platinum; Prognosis; Receptor, Notch1; Small Cell Lung Carcinoma; Survival Analysis; Transcription Factor HES-1; Treatment Outcome | 2020 |
Effect of Nano-Platinum on Proliferation and Apoptosis of Non-Small Cell Lung Cancer Cells via P53 Pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Nanoparticles; Platinum; Tumor Suppressor Protein p53 | 2021 |
Plasma levels of platinum-induced fatty acid [16:4n-3] do not affect response to platinum-based chemotherapy: A pilot study in non-small cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Humans; Lung Neoplasms; Pilot Projects; Platinum; Retrospective Studies; Tandem Mass Spectrometry | 2020 |
Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Nivolumab; Platinum; Prognosis; Retrospective Studies; Survival Rate; United States | 2021 |
Senescent T Cells as a Resistance Mechanism to Lung Cancer Immunotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Immunosenescence; Immunotherapy; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; T-Lymphocytes | 2021 |
Comparing Immunotherapies in Combination With Chemotherapy for Previously Untreated Advanced Nonsquamous NSCLC.
Topics: Antibodies, Monoclonal, Humanized; Double-Blind Method; Humans; Immunotherapy; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11).
Topics: Antibodies, Monoclonal, Humanized; Double-Blind Method; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
RNA-Seq Analysis of Cisplatin and the Monofunctional Platinum(II) Complex, Phenanthriplatin, in A549 Non-Small Cell Lung Cancer and IMR90 Lung Fibroblast Cell Lines.
Topics: Activating Transcription Factor 3; Carcinoma, Non-Small-Cell Lung; Cell Line; Cisplatin; Coordination Complexes; Down-Regulation; Fibroblasts; Humans; Lung; Lung Neoplasms; Organoplatinum Compounds; Phenanthridines; Phosphofructokinase-2; Platinum; Sequence Analysis, RNA; Up-Regulation | 2020 |
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Humans; Lung Neoplasms; Platinum; Prospective Studies | 2021 |
Platinum Nanoparticles Enhance Exosome Release in Human Lung Epithelial Adenocarcinoma Cancer Cells (A549): Oxidative Stress and the Ceramide Pathway are Key Players.
Topics: A549 Cells; Acetylcholinesterase; Acetylcysteine; Adenocarcinoma of Lung; Aniline Compounds; Benzylidene Compounds; Cell Proliferation; Cell Survival; Ceramides; Enzyme Activation; Exosomes; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Lutein; Metal Nanoparticles; Neoplasm Proteins; Oxidative Stress; Particle Size; Platinum; RNA, Messenger; Serum; Sphingomyelin Phosphodiesterase; Static Electricity | 2021 |
Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2021 |
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Female; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Platinum; Prospective Studies; Proto-Oncogene Mas; Proto-Oncogene Proteins | 2021 |
Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma: A case report.
Topics: Aged; Antibodies, Monoclonal, Humanized; Humans; Immunotherapy; Lung Neoplasms; Male; Platinum; Sarcoma | 2021 |
Combination treatment options for small-cell lung cancer - Authors' reply.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Etoposide; Humans; Lung Neoplasms; Platinum | 2021 |
Combination treatment options for small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Etoposide; Humans; Lung Neoplasms; Platinum | 2021 |
Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Platinum; Polymorphism, Single Nucleotide | 2021 |
UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
Topics: Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Platinum; Polymorphism, Genetic; Prospective Studies; Small Cell Lung Carcinoma | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antigens, Surface; Antineoplastic Agents; Antioxidants; Antiviral Agents; Aporphines; Atherosclerosis; Benzoyl Peroxide; beta Catenin; Biofilms; Biomarkers; Brain; Cannabis; Carcinoma, Squamous Cell; Case-Control Studies; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Child; China; Chlorides; Chlorophyll; Cholesterol, LDL; Coinfection; Corylus; Cross-Sectional Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Developmental Disabilities; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Electroencephalography; Environmental Exposure; Enzyme Inhibitors; Epilepsy, Generalized; Ethnicity; Female; Fertilization in Vitro; Fluorescent Dyes; Follow-Up Studies; Forecasting; Glutamate Carboxypeptidase II; Glycine; Half-Life; Head and Neck Neoplasms; Health Communication; Heart Ventricles; Hepacivirus; Hepatitis C; Heterosexuality; HIV Infections; Humans; Hypercholesterolemia; Immunoassay; Inhalation Exposure; Isocitrate Dehydrogenase; Laryngeal Neoplasms; Ligands; Light; Lipopolysaccharide Receptors; Liver Cirrhosis; Lung; Lung Neoplasms; Magnetic Resonance Imaging, Cine; Male; Maternal Age; Mechanical Phenomena; Mice; Mice, Nude; Mice, SCID; Microglia; MicroRNAs; Microscopy, Fluorescence; Microsomes, Liver; Middle Aged; Minority Groups; Mitochondrial Membrane Transport Proteins; Models, Biological; Molecular Structure; Molecular Weight; Monte Carlo Method; Muscle Hypotonia; Mutagenesis, Site-Directed; Mutation, Missense; Natriuretic Peptide, Brain; Neoplasms; Nickel; Nitric Oxide; Optical Imaging; Oxides; Particle Size; Particulate Matter; PCSK9 Inhibitors; Peptide Fragments; Phenotype; Photochemotherapy; Photosensitizing Agents; Phytochemicals; Piper; Placenta Growth Factor; Plant Extracts; Plant Leaves; Plant Stems; Platinum; Point-of-Care Testing; Population Surveillance; Postpartum Period; Pregnancy; Pregnancy, Twin; Prevalence; Prospective Studies; Prostatic Neoplasms; Pseudomonas aeruginosa; Pyridines; Pyridones; Racial Groups; Rats; Respiratory Physiological Phenomena; Retrospective Studies; Risk Factors; RNA, Long Noncoding; Semiconductors; Sexual and Gender Minorities; Sexual Behavior; Social Media; Sodium; Solubility; Stereoisomerism; Stochastic Processes; Structure-Activity Relationship; Substance-Related Disorders; Sustained Virologic Response; Sweat; Temperature; Time Factors; Tissue Distribution; Titanium; Transplantation, Heterologous; Tumor Cells, Cultured; Tungsten; Tyramine; United States; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Function, Left; Veterans; Xenograft Model Antitumor Assays; Young Adult | 2021 |
A rational targeted therapy for platinum-resistant small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Platinum; Topotecan | 2021 |
Neoadjuvant treatment of pembrolizumab plus platinum-doublet chemotherapy in stage IIIA squamous cell carcinoma of the lung: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Platinum | 2021 |
The Immunosuppression of Etoposide Deserves Attention in Chemoimmunotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Immunosuppression Therapy; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2021 |
Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC.
Topics: Drug Therapy, Combination; Humans; Lung Neoplasms; Pemetrexed; Platinum; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases | 2021 |
Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Lung Neoplasms; Male; Nivolumab; Platinum; Quality-Adjusted Life Years; Treatment Outcome; United States | 2021 |
Association of
Topics: Case-Control Studies; Genotype; Humans; Lung Neoplasms; Platinum; Polymorphism, Genetic | 2021 |
Hollow PtCo alloy nanospheres as a high-
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Catalase; Cell Line, Tumor; Cobalt; Humans; Lung Neoplasms; Metal Nanoparticles; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Nanospheres; Oxygen; Platinum; Powder Diffraction; Xenograft Model Antitumor Assays | 2021 |
The role of angiotensin-(1-7) on acquired platinum resistance-induced angiogenesis in non-small cell lung cancer in vitro and in vivo.
Topics: Angiotensin I; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Peptide Fragments; Phosphatidylinositol 3-Kinases; Platinum; Vascular Endothelial Growth Factor A | 2021 |
Polymorphisms in
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Platinum; Polymorphism, Single Nucleotide; Survival Rate | 2021 |
Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.
Topics: Antineoplastic Agents; Cross-Sectional Studies; Female; Humans; Lung Neoplasms; Male; Peripheral Nervous System Diseases; Platinum; Quality of Life; Taiwan | 2021 |
Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: a multicenter retrospective study using three propensity score analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Propensity Score; Renin-Angiotensin System; Retrospective Studies | 2021 |
Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation.
Topics: Adenocarcinoma of Lung; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Retrospective Studies | 2021 |
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lung Neoplasms; Platinum; Retrospective Studies | 2021 |
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; United States | 2021 |
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2021 |
Distinguishable Targeting of Non-Small Cell Lung Cancer Using Hyaluronan Functionalized Platinum Nanoclusters and Their Inhibition Behaviors of Proliferation, Invasion, Migration.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Hyaluronan Receptors; Hyaluronic Acid; Lung Neoplasms; Metal Nanoparticles; Platinum | 2021 |
EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Follow-Up Studies; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Platinum; Retrospective Studies; Treatment Outcome | 2022 |
Associated factors with constipation and health-related quality of life in lung cancer patients with platinum-based chemotherapy: A cross-sectional study.
Topics: Aged; Constipation; Cross-Sectional Studies; Drug Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Patient Health Questionnaire; Platinum; Quality of Life | 2021 |
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Platinum; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2022 |
First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
Topics: Aged; Antibodies, Monoclonal; Cost-Benefit Analysis; Etoposide; Humans; Lung Neoplasms; Medicare; Platinum; Small Cell Lung Carcinoma; United States | 2021 |
Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Complications; Diabetes Mellitus; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Mutation; Pemetrexed; Platinum; Probability; Proportional Hazards Models; Retrospective Studies; Taiwan; Treatment Outcome | 2021 |
More valuable than platinum: first-line pembrolizumab in advanced stage non-small-cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Platinum | 2017 |
Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Proportional Hazards Models; Taxoids | 2017 |
NOTCH1 Signaling Regulates Self-Renewal and Platinum Chemoresistance of Cancer Stem-like Cells in Human Non-Small Cell Lung Cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Mice; Neoplastic Stem Cells; Platinum; Receptor, Notch1; Signal Transduction | 2017 |
Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Disease-Free Survival; Ethnicity; Female; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Platinum; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome | 2017 |
Confused reference in the article entitle: pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer-focusing on DNA repair systems.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Repair; Humans; Lung Neoplasms; Pharmacogenetics; Platinum; Polymorphism, Single Nucleotide | 2017 |
Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Carboplatin; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Pemetrexed; Peptides; Platinum; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2017 |
Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Inflammation; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Monocytes; Neutrophils; Pemetrexed; Platelet Count; Platinum; Prognosis | 2017 |
Bio-fabrication of catalytic platinum nanoparticles and their in vitro efficacy against lungs cancer cells line (A549).
Topics: Antineoplastic Agents; Biological Transport; Catalysis; Cell Line, Tumor; Drug Stability; Humans; Lung Neoplasms; Metal Nanoparticles; Nitrophenols; Oxidation-Reduction; Particle Size; Platinum | 2017 |
Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Epistasis, Genetic; Female; Gene-Environment Interaction; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Reproducibility of Results | 2017 |
An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Caprylates; Caspases; Cell Line, Tumor; Cell Proliferation; Cisplatin; Coordination Complexes; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Humans; Isomerism; Lung Neoplasms; Mice; Mice, Inbred C57BL; Platinum; Prodrugs; Tissue Distribution; Transplantation, Homologous | 2017 |
Xeroderma pigmentosum complementation group D polymorphism toward lung cancer susceptibility survival and response in patients treated with platinum chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome; Xeroderma Pigmentosum | 2017 |
Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2018 |
Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Platinum; Protein Kinase Inhibitors | 2017 |
Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Metabolomics; Middle Aged; Neoplasm Staging; Platinum; Predictive Value of Tests; Prognosis | 2017 |
Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Platinum; Young Adult | 2018 |
Feasibility Trial of Oral UFT after Platinum-based Adjuvant Chemotherapy in Patients with Resected Non-small Cell Lung Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Tegafur; Uracil | 2017 |
Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
Topics: Adult; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prognosis; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Survival Rate; Young Adult | 2018 |
FePt-Cys nanoparticles induce ROS-dependent cell toxicity, and enhance chemo-radiation sensitivity of NSCLC cells in vivo and in vitro.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Survival; Chemoradiotherapy; Cisplatin; Cysteine; Humans; Lung Neoplasms; Magnetite Nanoparticles; Platinum; Reactive Oxygen Species; Treatment Outcome | 2018 |
Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Treatment Outcome | 2018 |
Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Consensus; Decision Making; Female; Geriatric Assessment; Humans; Lung Neoplasms; Male; Palliative Care; Platinum; Prospective Studies; Spain; Survival Analysis; Treatment Outcome | 2018 |
Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinorelbine | 2018 |
Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Therapy; ErbB Receptors; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Multisensor Imaging-From Sample Preparation to Integrated Multimodal Interpretation of LA-ICPMS and MALDI MS Imaging Data.
Topics: Antineoplastic Agents; Cisplatin; Elements; Humans; Laser Therapy; Lipids; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Molecular Imaging; Multimodal Imaging; Multivariate Analysis; Phosphorus; Platinum; Pleura; Specimen Handling; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2018 |
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Copper-Transporting ATPases; Female; Gastrointestinal Tract; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenomic Variants; Platinum; Polymorphism, Single Nucleotide; Proportional Hazards Models; Treatment Outcome; Young Adult | 2018 |
Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Republic of Korea; Survival Analysis; Treatment Outcome | 2018 |
Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy.
Topics: A549 Cells; Activins; Adenocarcinoma of Lung; Animals; Carboplatin; Cell Line, Tumor; Cell Survival; Follistatin; Humans; Lung Neoplasms; Male; Mice; Platinum; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Immunotherapy in patients who have NSCLC without EGFR or ALK mutations.
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multicenter Studies as Topic; Pemetrexed; Platinum; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2018 |
Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nutrition Assessment; Platinum; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2018 |
Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Genetic Variation; Genome-Wide Association Study; Genotyping Techniques; Germ-Line Mutation; Histone-Lysine N-Methyltransferase; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Prognosis; Spain | 2018 |
Avelumab in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Platinum | 2018 |
Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer Patients.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cohort Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Survival Analysis; United States | 2019 |
Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasm Metastasis; Platinum; Standard of Care; Survival Analysis; Treatment Outcome | 2018 |
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer.
Topics: Adult; Aged; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Up-Regulation | 2019 |
Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Platelets; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Leukocyte Count; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Platelet Count; Platinum; Prognosis; ROC Curve; Treatment Outcome | 2019 |
Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylases; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Nude; Platinum; Repressor Proteins; Signal Transduction; Telomere-Binding Proteins | 2018 |
Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Genotype; Glucuronosyltransferase; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Small Cell Lung Carcinoma | 2018 |
A safe and efficacious Pt(ii) anticancer prodrug: design, synthesis, in vitro efficacy, the role of carrier ligands and in vivo tumour growth inhibition.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Proliferation; Coordination Complexes; Crystallography, X-Ray; Drug Design; Humans; Ligands; Liposomes; Lung Neoplasms; Mice; Molecular Conformation; Platinum; Prodrugs; Transplantation, Heterologous | 2019 |
Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Platinum | 2019 |
Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Malnutrition; Middle Aged; Platinum; Retrospective Studies; Treatment Outcome | 2019 |
Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Repositioning; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; High-Throughput Screening Assays; Humans; Lung Neoplasms; Microscopy, Fluorescence; Pancreatic Neoplasms; Platinum; Prognosis | 2019 |
Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Latin America; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Platinum; Pleural Neoplasms; Progression-Free Survival; Thoracic Surgical Procedures | 2019 |
Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cohort Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome | 2019 |
[Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA-Directed DNA Polymerase; Etoposide; Genetic Variation; Humans; Lung Neoplasms; Platinum; Polymorphism, Single Nucleotide; Prognosis; Regression Analysis; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genetic Variation; Genomics; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Palliative Care; Pemetrexed; Peritoneal Neoplasms; Platinum; Treatment Outcome; Young Adult | 2019 |
Pursuing Specific Chemotherapy of Orthotopic Breast Cancer with Lung Metastasis from Docking Nanoparticles Driven by Bioinspired Exosomes.
Topics: Animals; Breast Neoplasms; Drug Delivery Systems; Exosomes; Female; Humans; Laurates; Lung Neoplasms; Mice; Nanoparticles; Platinum; Prodrugs; RAW 264.7 Cells; Serum Albumin, Human | 2019 |
The vertebral 3'-deoxy-3'-
Topics: Adult; Aged; Antineoplastic Agents; Cell Proliferation; Chemoradiotherapy; Female; Fluorine Radioisotopes; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed | 2019 |
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Repair; Female; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Platinum; Pleural Neoplasms; Survival Analysis; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Young Adult | 2019 |
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC.
Topics: Adult; Aged; Aged, 80 and over; DNA Damage; Humans; Lung Neoplasms; Middle Aged; Mutation; Platinum; Small Cell Lung Carcinoma; Tumor Burden | 2019 |
Computed tomography-guided platinum microcoil lung surgery: A cross-sectional study.
Topics: Aged; Cross-Sectional Studies; Female; Humans; Lung; Lung Neoplasms; Male; Platinum; Radiography, Interventional; Retrospective Studies; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2019 |
Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Platinum; Retrospective Studies | 2020 |
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Platinum; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Survival Rate; Young Adult | 2020 |
Evaluation of biological synthesized platinum nanoparticles using Ononidis radix extract on the cell lung carcinoma A549.
Topics: A549 Cells; Cell Cycle; Fabaceae; Humans; Lung Neoplasms; Metal Nanoparticles; Plant Extracts; Platinum | 2019 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Topics: BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Clinical Trials as Topic; Disease-Free Survival; DNA-Binding Proteins; Drug Therapy; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Nuclear Proteins; Platinum; RNA, Messenger | 2013 |
XBP1 promoter polymorphism modulates platinum-based chemotherapy gastrointestinal toxicity for advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; DNA-Binding Proteins; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Tract; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Genetic; Promoter Regions, Genetic; Regulatory Factor X Transcription Factors; Transcription Factors; X-Box Binding Protein 1 | 2013 |
In vivo monitoring the process of tumor growth, metastasis and bacterial infection expressing GFP via real-time optical imaging.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Computer Systems; Escherichia coli Infections; Fluorescence; Green Fluorescent Proteins; Humans; Kanamycin; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasms; Optical Imaging; Peritoneal Neoplasms; Platinum; Rats; Subcutaneous Tissue | 2013 |
The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Survival Rate | 2014 |
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Palliative Care; Pemetrexed; Platinum; Pleural Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Platinum; Vinblastine; Vinorelbine | 2013 |
Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dinucleoside Phosphates; DNA Adducts; Humans; Leukocyte Common Antigens; Leukocytes, Mononuclear; Lewis X Antigen; Lung Neoplasms; Middle Aged; Neoplastic Cells, Circulating; Platinum; Tumor Cells, Cultured | 2013 |
Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Female; Glutamates; Guanine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Observational Studies as Topic; Pemetrexed; Platinum; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; United States | 2013 |
Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2013 |
Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Risk Factors; Treatment Outcome | 2013 |
[Comparison of platinum-containing doublet chemotherapy and liposome paclitaxel monotherapy for the treatment of elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Liposomes; Lung Neoplasms; Male; Paclitaxel; Platinum; Treatment Outcome | 2013 |
[Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate | 2013 |
Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Platinum; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Survival Rate | 2014 |
Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Genotype; Haplotypes; Hematologic Diseases; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis | 2014 |
HIF1α genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC.
Topics: Aged; Alleles; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Coordination Complexes; Disease-Free Survival; Female; Genotype; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide | 2013 |
Rational design of polyion complex nanoparticles to overcome cisplatin resistance in cancer therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Mice; Mice, Nude; Nanoconjugates; Platinum; Prodrugs; Xenograft Model Antitumor Assays | 2014 |
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Enhancer Elements, Genetic; Female; Genotype; Humans; Linkage Disequilibrium; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Risk Factors; Thymidylate Synthase | 2014 |
Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Platinum; Polymorphism, Single Nucleotide; Proportional Hazards Models; Transcription Factors; Treatment Outcome | 2014 |
Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Platinum; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Risk Factors; Transcription Factors; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2014 |
[Efficacies and toxicities of different platinum-based combination chemotherapies for patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Treatment Outcome | 2014 |
Delivery of platinum(IV) drug to subcutaneous tumor and lung metastasis using bradykinin-potentiating peptide-decorated chitosan nanoparticles.
Topics: Animals; Antineoplastic Agents; Capillary Permeability; Cell Death; Cell Line, Tumor; Cell Proliferation; Chitosan; Drug Delivery Systems; Endocytosis; Fluorescein-5-isothiocyanate; Humans; Lung Neoplasms; Male; Mice, Inbred ICR; Nanoparticles; Oligopeptides; Particle Size; Platinum; Spectroscopy, Near-Infrared; Spheroids, Cellular; Subcutaneous Tissue; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Survival Rate; Vascular Cell Adhesion Molecule-1 | 2014 |
The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients.
Topics: Adenosine Triphosphatases; Adult; Aged; Cation Transport Proteins; Copper-Transporting ATPases; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide | 2014 |
Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Proportional Hazards Models | 2014 |
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors | 2014 |
Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Pemetrexed; Platinum; Polymorphism, Single Nucleotide; Proportional Hazards Models; Retrospective Studies; Thymidylate Synthase | 2014 |
Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Platinum; Pleural Neoplasms; Prognosis; Proportional Hazards Models; Serum Albumin | 2014 |
Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Retrospective Studies; Risk Factors; Thromboembolism; Treatment Outcome; Young Adult | 2014 |
Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Down-Regulation; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Platinum; Retrospective Studies; Sex Factors; Treatment Outcome | 2015 |
PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carrier Proteins; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2014 |
Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Follow-Up Studies; HSP70 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Treatment Outcome | 2014 |
Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Follow-Up Studies; Gene Expression; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Platinum; Polycomb Repressive Complex 2; Prognosis; Treatment Outcome | 2014 |
Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Hydrolysis; Lung Neoplasms; Platinum; Prodrugs; Valproic Acid | 2014 |
WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients.
Topics: Antineoplastic Agents; CCN Intercellular Signaling Proteins; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins | 2014 |
The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Vascular Endothelial Growth Factor A | 2015 |
Cellular effects of industrial metal nanoparticles and hydrophilic carbon black dispersion.
Topics: Cell Survival; Cells, Cultured; Gold; Humans; Hydrophobic and Hydrophilic Interactions; Keratinocytes; Lung Neoplasms; Metal Nanoparticles; Mitochondria; Oxidative Stress; Platinum; Reactive Oxygen Species; Silver; Soot; Time Factors; Tumor Cells, Cultured | 2014 |
Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Odds Ratio; Platinum; Registries; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome | 2014 |
The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Platinum; Prospective Studies; Protein Kinase Inhibitors; Risk Factors; Treatment Outcome | 2015 |
Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; MyoD Protein; Myoglobin; Myosin Type II; Platinum; Pleural Effusion, Malignant; Prognosis; Ribonucleoside Diphosphate Reductase; Thymidylate Synthase; Tubulin; Tumor Suppressor Proteins | 2015 |
Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cohort Studies; DNA Modification Methylases; DNA Repair Enzymes; Female; Glutathione Peroxidase; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Peripheral Nervous System Diseases; Peroxidases; Platinum; Polymorphism, Single Nucleotide; Risk Factors; Taxoids; Tumor Suppressor Proteins | 2015 |
ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide; RNA, Messenger | 2015 |
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Treatment Failure | 2015 |
XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Demography; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Genetic Association Studies; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Platinum; Polymorphism, Single Nucleotide; Prognosis; Transcription Factors | 2015 |
The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Vinblastine; Vinorelbine | 2015 |
Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cyclooxygenase 2; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2015 |
[Sequential Treatment of Advanced Squamous Lung Cancer:
First-line Gemcitabine +/- platinum Followed by Second-line Taxanes +/- platinum Versus Reverse Sequence].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids | 2015 |
Genome-wide Association Study on Platinum-induced Hepatotoxicity in Non-Small Cell Lung Cancer Patients.
Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Demography; Ethnicity; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide; Risk Factors | 2015 |
Monocyte nadir is a possible indicator for neutrophil nadir during lung cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Monocytes; Neoplasm Staging; Neutrophils; Observational Studies as Topic; Outcome Assessment, Health Care; Platinum; Retrospective Studies | 2017 |
The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Ribonucleoside Diphosphate Reductase; Risk Factors; Treatment Outcome; Tumor Burden; Tumor Suppressor Proteins | 2015 |
Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; DNA; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum | 2015 |
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Nestin; Pemetrexed; Platinum; Pleural Neoplasms; Pneumonectomy; Prognosis; Sarcoma; Stem Cell Factor | 2015 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Hospitals, University; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Turkey | 2015 |
Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-bcl-2 | 2015 |
Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
Topics: Adult; Aged; Aged, 80 and over; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Demography; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Proto-Oncogene Proteins p21(ras); RNA, Messenger; Thymidylate Synthase; Treatment Outcome | 2016 |
Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Europe; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Platinum; Retreatment; Treatment Outcome | 2015 |
Gold(III) compounds-mediated inhibition of lung cancer cell proliferation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cold Temperature; Coordination Complexes; Cricetulus; Fibroblasts; Humans; Imidazoles; Lung Neoplasms; Phenanthrolines; Platinum; Structure-Activity Relationship | 2016 |
Weight Loss Associated with Platinum-Based Chemotherapy in Patients with Advanced Lung Cancer.
Topics: Aged; Antineoplastic Agents, Alkylating; Female; Humans; Leukopenia; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome; Weight Loss | 2016 |
[Effect of polymorphisms of NF-κB and PXR on platinum-based chemotherapy for non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Genotype; Humans; Lung Neoplasms; NF-kappa B; Platinum; Polymorphism, Genetic; Pregnane X Receptor; Receptors, Steroid; Transcription Factor RelA | 2016 |
The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
Topics: Accidental Falls; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chi-Square Distribution; Female; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Ovarian Neoplasms; Peripheral Nervous System Diseases; Platinum; Prospective Studies; Severity of Illness Index; Taxoids | 2016 |
Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mitochondrial Proteins; Neoplasm Grading; Neoplasm Staging; Platinum; Prognosis; Treatment Outcome | 2017 |
PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Topics: Antineoplastic Agents; Apoptosis; Carrier Proteins; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cluster Analysis; Cyclin-Dependent Kinases; DNA-Binding Proteins; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Mitosis; Nuclear Proteins; Phosphorylation; Platinum; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones | 2016 |
Clinical Significance of Long Non-Coding RNA CASC8 rs10505477 Polymorphism in Lung Cancer Susceptibility, Platinum-Based Chemotherapy Response, and Toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Platinum; Polymorphism, Single Nucleotide; Prognosis; RNA, Long Noncoding; Sex Factors | 2016 |
[Evaluation of the Efficacy and Safety of Platinum Doublet Re-Challenge Chemotherapy in Patients with Recurrent Advanced Non-Small Cell Lung Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Recurrence; Retrospective Studies | 2016 |
Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA-(Apurinic or Apyrimidinic Site) Lyase; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Proportional Hazards Models; ROC Curve; Treatment Outcome | 2016 |
ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Humans; Lung Neoplasms; Platinum; Prospective Studies | 2017 |
Can body composition be used to optimize the dose of platinum chemotherapy in lung cancer? A feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum | 2017 |
The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
Topics: 5' Untranslated Regions; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; DNA-Binding Proteins; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Nuclear Proteins; Ovarian Neoplasms; Pharmacogenomic Variants; Platinum; Polymorphism, Genetic; Survival Analysis; Transcription Factors; Treatment Outcome | 2016 |
Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Survival Analysis; Vitamin D; Vitamin D Deficiency | 2017 |
Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
Topics: Antineoplastic Agents; Cell Line; Cisplatin; DNA Adducts; DNA Repair; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Phosphoproteins; Platinum; Sulfonamides; Transcription Factor TFIIB; Transcription Factors | 2017 |
Lung cancer: ET - platinum therapy comes home.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Platinum | 2017 |
Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
Topics: Adult; Aged; Cisplatin; Female; Humans; Hyperthermia, Induced; Infusions, Intralesional; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Perfusion; Platinum; Pleural Cavity; Pleural Effusion, Malignant; Pleural Neoplasms; Prospective Studies; Thoracic Surgery, Video-Assisted | 2017 |
Caspase 8 polymorphisms contribute to the prognosis of advanced lung adenocarcinoma patients after platinum-based chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Caspase 8; China; Disease-Free Survival; Female; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Quality of Life | 2017 |
Osimertinib improves progression-free survival in NSCLC.
Topics: Acrylamides; Aniline Compounds; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Progression-Free Survival; Protein Kinase Inhibitors | 2017 |
Erythema elevatum diutinum as a paraneoplastic syndrome in a patient with pulmonary lymphoepithelioma-like carcinoma.
Topics: Antineoplastic Agents; Biopsy; Carcinoma; Erythema; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Paraneoplastic Syndromes; Platinum; Remission Induction; Skin; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Gene Frequency; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Prognosis; Ubiquitin-Protein Ligases | 2008 |
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Pleural Effusion, Malignant; Prognosis; Proto-Oncogene Proteins c-bcl-2; Recurrence; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Patient attitudes towards chemotherapy and survival: a prospective observational study in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Attitude to Health; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Observation; Platinum; Prospective Studies | 2009 |
Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2009 |
[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paraffin Embedding; Platinum; Proportional Hazards Models; RNA, Messenger; Survival Rate | 2009 |
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Medical Oncology; Platinum; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma | 2009 |
Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment.
Topics: Arsenic; Cell Line, Tumor; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Liposomes; Lung Neoplasms; Molecular Structure; Platinum | 2009 |
[Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2009 |
Smoking intensity, oxidative stress and chemotherapy in nonsmall cell lung cancer: a correlated prognostic study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxidative Stress; Platinum; Prognosis; Smoking | 2009 |
Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer.
Topics: Carboplatin; Cisplatin; Etoposide; Female; Genes; Genome; Humans; Inuit; Lung Neoplasms; Male; Middle Aged; Nerve Tissue Proteins; Platinum; Polymorphism, Single Nucleotide; R-SNARE Proteins; Small Cell Lung Carcinoma | 2010 |
High retention and safety of percutaneously implanted endovascular embolization coils as fiducial markers for image-guided stereotactic ablative radiotherapy of pulmonary tumors.
Topics: Aged; Artifacts; Chest Tubes; Embolization, Therapeutic; Female; Fiducial Markers; Foreign-Body Migration; Gold; Humans; Lung Neoplasms; Male; Platinum; Pneumothorax; Radiography, Interventional; Radiosurgery; Retrospective Studies; Stents; Tomography, X-Ray Computed | 2011 |
[Comparison between single-agent and platinum-doublet chemotherapy in elderly patients with non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Platinum; Retrospective Studies; Survival Rate | 2010 |
Multifunctional FePt nanoparticles for radiation-guided targeting and imaging of cancer.
Topics: Animals; Cell Line, Tumor; Humans; Iron; Lung Neoplasms; Metal Nanoparticles; Mice; Mice, Nude; Microscopy, Fluorescence; Molecular Probe Techniques; Organ Specificity; Platinum; Tissue Distribution; Treatment Outcome | 2011 |
Stability of markers used for real-time tumor tracking after percutaneous intrapulmonary placement.
Topics: Carcinoma, Non-Small-Cell Lung; Exhalation; Female; Fiducial Markers; Foreign-Body Migration; Humans; Linear Models; Lung Neoplasms; Male; Platinum; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Tumor Burden | 2011 |
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Histone Chaperones; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Platinum; Predictive Value of Tests; RNA, Messenger; Treatment Outcome; Tubulin; Tumor Suppressor Protein p53 | 2011 |
Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Transformed; Cell Line, Tumor; DNA Repair; DNA Repair Enzymes; Eukaryotic Initiation Factor-3; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Neoplasm Staging; NIH 3T3 Cells; Platinum; Treatment Outcome; Young Adult | 2011 |
Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Deoxycytidine; DNA Repair; ErbB Receptors; Female; Gemcitabine; Glutathione; Glutathione Peroxidase; Humans; Lung Neoplasms; Male; Platinum; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-raf; Taxoids | 2011 |
[Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Platinum; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2011 |
[Nimotuzumab in combination with chemotherapy in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Agranulocytosis; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Remission Induction; Retrospective Studies; Thrombocytopenia; Vomiting | 2011 |
The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Predictive Value of Tests; Proportional Hazards Models; Quinazolines; Smoking; Taxoids; Tubulin | 2012 |
Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Caspase 7; Drug Therapy; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Platinum; Polymorphism, Single Nucleotide; Prognosis; Regression Analysis; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
[Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Retrospective Studies; Thymidylate Synthase; Treatment Outcome; Young Adult | 2012 |
Analysis of the DNA damage produced by a platinum-acridine antitumor agent and its effects in NCI-H460 lung cancer cells.
Topics: Acridines; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cell-Free System; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Cisplatin; DNA Adducts; DNA Damage; DNA, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Platinum; Spectrometry, Mass, Electrospray Ionization | 2012 |
Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Galectin 3; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Survival Analysis | 2012 |
Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs.
Topics: Antineoplastic Agents; Arsenic; Biomarkers; Carboplatin; Chile; Cisplatin; Cluster Analysis; Creatinine; Female; Humans; Linear Models; Lung Neoplasms; Male; Multivariate Analysis; Platinum; Selenium | 2012 |
The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; C-Reactive Protein; Female; Humans; Inflammation; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prognosis; Severity of Illness Index; Treatment Outcome | 2012 |
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymerase Chain Reaction; Polymorphism, Genetic; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Taiwan; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2012 |
ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Platinum | 2012 |
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Lymph Nodes; Male; Methotrexate; Middle Aged; Neoplasm Staging; Perioperative Care; Platinum; Pneumonectomy; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Caspase 10; Caspase 8; Cisplatin; Female; Gene Frequency; Haplotypes; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide | 2012 |
Tissue platinum concentration and tumor response in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Platinum; Survival Analysis | 2012 |
Structure-cytotoxicity relationship for different types of mononuclear platinum(II) complexes with 5,7-ditertbutyl-1,2,4-triazolo[1,5-a]pyrimidine.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Female; Humans; Lung Neoplasms; Platinum; Pyrimidines; Structure-Activity Relationship; X-Ray Diffraction | 2012 |
Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Induction Chemotherapy; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Quinazolines | 2012 |
Outcomes after adjuvant platinum-based chemotherapy in elderly NSCLC patients with T4 disease.
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; SEER Program; Survival Rate | 2013 |
Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Repair; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Retrospective Studies | 2012 |
Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Tomography, X-Ray Computed | 2013 |
Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Adducts; DNA, Neoplasm; Factor VIII; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, SCID; Microdialysis; Models, Biological; Neoplasm Proteins; Neovascularization, Pathologic; Platinum; Specific Pathogen-Free Organisms; Tissue Distribution; Xenograft Model Antitumor Assays | 2002 |
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Topotecan as first-line therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan | 2003 |
Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes.
Topics: Adult; Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Irinotecan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Platinum; Prospective Studies; Taxoids | 2003 |
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Codon; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Genotype; Humans; Linkage Disequilibrium; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; RNA, Messenger; Time Factors; Treatment Outcome | 2004 |
Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: II. High-dose cisplatin is well tolerated by the native lung tissue.
Topics: Animals; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Hemodynamics; Hyperthermia, Induced; Lung; Lung Compliance; Lung Neoplasms; Neoadjuvant Therapy; Platinum; Pulmonary Gas Exchange; Respiratory Distress Syndrome; Swine; Vascular Resistance | 2004 |
Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Perioperative Care; Platinum; Pneumonectomy; Survival Rate; Treatment Outcome | 2005 |
[Bronchial artery embolisation using platinum coils in 52 patients with severe pulmonary hemorrhage].
Topics: Adult; Aged; Aged, 80 and over; Bronchial Arteries; Embolization, Therapeutic; Female; Hemoptysis; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Platinum; Recurrence; Retrospective Studies | 2005 |
Platinum-acridinylthiourea conjugates show cell line-specific cytotoxic enhancement in H460 lung carcinoma cells compared to cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; DNA Adducts; Humans; Lung Neoplasms; Platinum; Urea | 2005 |
Element array by scanning X-ray fluorescence microscopy after cis-diamminedichloro-platinum(II) treatment.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chelating Agents; Cisplatin; Drug Interactions; Drug Resistance, Neoplasm; Glutathione; Humans; Inactivation, Metabolic; Lung Neoplasms; Metallothionein; Microscopy, Fluorescence; Platinum; Spectrometry, X-Ray Emission; Zinc | 2005 |
[Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Repair; DNA-Binding Proteins; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Prospective Studies; Xeroderma Pigmentosum Group D Protein | 2005 |
[Reverse effect of genetically modified adenovirus H101 on drug-resistance of A549/DDP cells to cisplatin].
Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; DNA Topoisomerases, Type II; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione Transferase; Humans; Inhibitory Concentration 50; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Oncolytic Viruses; Platinum | 2005 |
A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Neutropenia; Paclitaxel; Platinum; Survival Rate; Time Factors | 2005 |
Pharmacokinetics after endovascular lung perfusion with Cisplatin.
Topics: Animals; Antineoplastic Agents; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; DNA Adducts; Lung Neoplasms; Platinum; Pulmonary Artery; Random Allocation; Swine | 2006 |
Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Europe; Gemcitabine; Humans; Japan; Lung Neoplasms; Platinum; Retrospective Studies; Survival Rate; Taxoids; United States; Vinblastine; Vinorelbine | 2006 |
Role of platinum-based radio-chemotherapy for locally advanced non-small-cell lung cancer: possible influence of type of platinum on survival data.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Platinum; Survival Analysis | 2006 |
Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Platinum; Radiotherapy; Treatment Outcome | 2006 |
Quality of life assessment in the TAX 326 study.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Patient Compliance; Platinum; Psychomotor Performance; Quality of Life; Sickness Impact Profile; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Synthesis and in vitro cytotoxicity of novel lipophilic (diamine)platinum(II) complexes of salicylate derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Diamines; Drug Screening Assays, Antitumor; Humans; Liposomes; Lung Neoplasms; Platinum; Salicylates; Solubility; Solvents; Spectrum Analysis; Stomach Neoplasms | 2007 |
Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition).
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytotoxins; Evidence-Based Medicine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Platinum; Quality of Life; Treatment Outcome | 2007 |
The cigarette burden (measured by the number of pack-years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Risk Factors; Smoking; Treatment Outcome | 2008 |
Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Protein-Tyrosine Kinases; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent.
Topics: Bleomycin; Drug Therapy, Combination; Dysgerminoma; Humans; Lung Neoplasms; Lymph Node Excision; Male; Platinum; Pneumonectomy; Retroperitoneal Neoplasms; Testicular Neoplasms; Vinblastine | 1980 |
[Pharmacokinetic of platin in plasma and urine of man under 1-, 8-, and 24 h-infusion with cis-dichlorodiamine-platin (II) (cis-DDP) (author's transl)].
Topics: Adult; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Humans; Infusions, Parenteral; Kinetics; Lung Neoplasms; Lymphoma; Male; Middle Aged; Ovarian Neoplasms; Platinum; Testicular Neoplasms | 1982 |
Cytotoxic effects of long-term circulating ultrafiltrable platinum species and limited efficacy of haemodialysis in clearing them.
Topics: Adenocarcinoma; Cell Survival; Cisplatin; Drug Overdose; Female; Humans; Lung Neoplasms; Middle Aged; Platinum; Renal Dialysis; Renal Insufficiency; Tumor Cells, Cultured | 1994 |
Considerations on radiotherapy dose intensity for limited small cell lung cancer.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms; Platinum; Radiotherapy Dosage; Time Factors | 1994 |
Pharmacokinetics of cisplatin instilled into the pleural cavity following panpleuropneumonectomy in patients with malignant pleurisy due to lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Instillation, Drug; Lung Neoplasms; Male; Middle Aged; Platinum; Pleura; Pleural Effusion, Malignant; Pleurisy; Pneumonectomy; Prognosis | 1993 |
In situ lung perfusion with cisplatin. An experimental study.
Topics: Animals; Cisplatin; Lung; Lung Neoplasms; Perfusion; Platinum; Pulmonary Gas Exchange; Swine | 1993 |
Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Resistance, Neoplasm; Etoposide; Female; Frontal Lobe; Humans; Liver Neoplasms; Lung Neoplasms; Methotrexate; Middle Aged; Paclitaxel; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms; Vincristine | 1996 |
Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cyclobutanes; DNA Adducts; DNA, Neoplasm; Humans; Hyperthermia, Induced; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum; Tumor Cells, Cultured | 1997 |
Concurrent daily carboplatin and accelerated hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Radiotherapy Dosage; Survival Analysis | 1997 |
Internal iliac arterial infusion chemotherapy for rabbit invasive bladder cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Iliac Artery; Infusions, Intra-Arterial; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Invasiveness; Platinum; Rabbits; Urinary Bladder Neoplasms | 1997 |
Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Hypotonic Solutions; Intraoperative Care; Lung Neoplasms; Male; Middle Aged; Platinum; Pleural Effusion, Malignant; Pleurisy; Retrospective Studies; Survival Rate; Thoracotomy | 1997 |
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Deoxycytidine; DNA; DNA Adducts; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorometry; Gemcitabine; Humans; Intracellular Fluid; Lung Neoplasms; Mice; Ovarian Neoplasms; Platinum; RNA; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Effects of lipo prostaglandin E1 on distribution of cis-diamminedichloroplatinum in lung metastasis derived from Dunn osteosarcoma cell-inoculated mouse foot-pad.
Topics: Alprostadil; Animals; Cisplatin; Hindlimb; In Situ Nick-End Labeling; Lung Neoplasms; Male; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Osteosarcoma; Platinum; Skin Neoplasms; Tissue Distribution | 1999 |
Value of bronchial artery embolisation with platinum coils in tumorous pulmonary bleeding.
Topics: Aged; Blood Vessel Prosthesis; Bronchial Arteries; Carcinoma, Bronchogenic; Embolization, Therapeutic; Female; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polyethylene Terephthalates; Survival Analysis | 2000 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Combination radical surgery and multiple sequential chemotherapy for the treatment of advanced carcinoma of the testis (stage III).
Topics: Adolescent; Adult; Antineoplastic Agents; Bleomycin; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, Combination; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Platinum; Testicular Neoplasms; Vinblastine | 1976 |
[Antineoplastic properties of complex compounds of platinum(II)].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; L-Lactate Dehydrogenase; Leukemia L1210; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Platinum; Syndrome | 1976 |
Metastatic choriocarcinoma with coexistent term pregnancy following four recurrent consecutive moles.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Hydatidiform Mole; Lung Neoplasms; Methotrexate; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms | 1992 |
Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colonic Neoplasms; Diamines; Drug Resistance; Humans; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Malonates; Mammary Neoplasms, Experimental; Melanoma, Experimental; Mice; Mice, Nude; Molecular Structure; Platinum; Structure-Activity Relationship; Tumor Cells, Cultured | 1992 |
Reduced drug accumulation in a newly established human lung squamous-carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
Topics: Carcinoma, Squamous Cell; Cell Division; Cell Line; Cisplatin; Drug Resistance; Humans; Lung Neoplasms; Platinum; Tetrazolium Salts; Thiazoles | 1992 |
[Pharmakinetics of carboplatin in cancer patients].
Topics: Adult; Breast Neoplasms; Carboplatin; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Platinum | 1991 |
Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II).
Topics: Adenocarcinoma; Breast Neoplasms; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; DNA; Drug Resistance; Glutathione Transferase; Humans; Lung Neoplasms; Melanoma; Neoplasms; Organoplatinum Compounds; Platinum; Sulfhydryl Compounds; Tumor Cells, Cultured | 1991 |
Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Topics: Antineoplastic Agents; Biological Assay; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Humans; Lung Neoplasms; Organoplatinum Compounds; Platinum; Tumor Cells, Cultured | 1991 |
[Evaluation of carboplatin administration into the serous cavity in the treatment of malignant effusion].
Topics: Aged; Carboplatin; Drug Evaluation; Female; Humans; Injections, Intralesional; Lung Neoplasms; Male; Middle Aged; Platinum; Pleural Effusion, Malignant | 1991 |
The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.
Topics: Carcinoma, Small Cell; Cell Line; Cisplatin; DNA; DNA, Neoplasm; Drug Resistance; Humans; Lung Neoplasms; Platinum; Tumor Cells, Cultured | 1990 |
A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance.
Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Cell Line; Cisplatin; Coloring Agents; Drug Resistance; Drug Screening Assays, Antitumor; Glutathione; Humans; Lung Neoplasms; Organoplatinum Compounds; Platinum; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1990 |
Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.
Topics: Adult; Aged; Biopsy; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diffusion; Drug Administration Schedule; Female; Fiber Optic Technology; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Prospective Studies; Spectrophotometry, Atomic | 1990 |
Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Platinum; Regression Analysis; Remission Induction | 1990 |
Diagnosis and treatment of pulmonary metastases from cervical carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lung Neoplasms; Middle Aged; Platinum; Retrospective Studies; Risk Factors; Survival Analysis; Uterine Cervical Neoplasms | 1990 |
Comparison of the effects of intra-arterial and intravenous cisplatin on both limb tumor and lung metastases of transitional cell carcinoma RBT-1 in rats.
Topics: Animals; Carcinoma, Transitional Cell; Cisplatin; Female; Hindlimb; Infusions, Intra-Arterial; Infusions, Intravenous; Kidney; Lung; Lung Neoplasms; Neoplasm Transplantation; Platinum; Rats; Rats, Inbred Strains | 1990 |
Effect of bis(bilato)-1,2-cyclohexanediammineplatinum(II) complexes on lung metastasis of B16-F10 melanoma cells in mice.
Topics: Animals; Cyclohexylamines; Injections, Intravenous; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred ICR; Mice, Inbred Strains; Organoplatinum Compounds; Platinum; Solutions; Tissue Distribution | 1990 |
Kinetics of cisplatin in a patient with lung carcinoma on continuous ambulatory peritoneal dialysis.
Topics: Cisplatin; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Platinum | 1990 |
[The use of direct current in the local destruction of cancer tissues].
Topics: Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Dogs; Electric Stimulation Therapy; Electrodes; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Necrosis; Platinum; Tissue Distribution | 1989 |
Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line.
Topics: Carcinoma, Small Cell; Cell Line; Cell Survival; Cisplatin; DNA; Docosahexaenoic Acids; Drug Resistance; Fatty Acids; Glutathione; Humans; Lung Neoplasms; Phospholipids; Platinum; Sphingolipids; Tumor Cells, Cultured | 1989 |
[Clinical studies of bronchial arterial infusion of CDDP for the treatment of lung cancer--research on the platinum concentration in the tumor and pulmonary parenchyma].
Topics: Aged; Bronchial Arteries; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Infusions, Intra-Arterial; Lung; Lung Neoplasms; Male; Middle Aged; Platinum | 1989 |
High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer.
Topics: Adult; Aged; California; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged; Peripheral Nervous System Diseases; Pilot Projects; Platinum; Saline Solution, Hypertonic | 1986 |
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Female; Glomerular Filtration Rate; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Platinum | 1987 |
Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
Topics: Adult; Aged; Cisplatin; Female; Humans; Kidney Function Tests; Kinetics; Lung Neoplasms; Male; Middle Aged; Neoplasms; Platinum; Teratoma; Ultrafiltration | 1986 |
New drugs on the horizon in bronchogenic carcinoma.
Topics: Amines; Animals; Antineoplastic Agents; Azacitidine; Bleomycin; Carcinoma, Bronchogenic; Carmustine; Cyclic P-Oxides; Cyclophosphamide; Dimethylamines; Doxorubicin; Ethylamines; Evaluation Studies as Topic; Humans; Ketones; Lung Neoplasms; Neoplasms, Experimental; Nitrosourea Compounds; Organophosphorus Compounds; Oxazines; Piperazines; Platinum; Triazines | 1972 |
Bronchogenic carcinoma: new drugs available for study.
Topics: Animals; Antineoplastic Agents; Azacitidine; Carcinoma, Bronchogenic; Chromomycins; Cyclic P-Oxides; Cyclophosphamide; Half-Life; Humans; Kinetics; Lung Neoplasms; Organometallic Compounds; Organophosphorus Compounds; Oxazines; Platinum | 1973 |
Some preliminary observations during the phase I clinical testing of cis-dichlorodiammineplatinum. II.
Topics: Adult; Amines; Breast Neoplasms; Carcinoma, Bronchogenic; Chlorides; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Platinum; Stomach Neoplasms | 1973 |